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All three members of the peroxisome 
proliferator-activated receptors 
(PPAR-α, -δ and -γ) are key regulators 
of human energy metabolism 
and candidate genes for insulin 
resistance. In this thesis, the effect 
of single nucleotide polymorphisms 
(SNPs) in the PPAR genes on insulin 
sensitivity was investigated at the 
whole body and tissue-specific level. 
The results demonstrate that SNPs 
in all PPAR genes may affect insulin 
sensitivity, suggesting that variation 
in the PPAR genes could also 
influence the risk of type 2 diabetes 
mellitus.
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ABSTRACT: 
The pathogenesis of type 2 diabetes mellitus (T2DM) is multifactorial and incompletely 
understood. Insulin resistance and impaired insulin secretion characterize T2DM. Both 
environmental and genetic factors contribute to insulin resistance. The peroxisome 
proliferator-activated receptors (PPARs) are nuclear receptors involved in many cellular 
processes including energy metabolism. A single nucleotide polymorphism (SNP) of the 
(PPAR) –γ gene results in the Pro12Ala polymorphism. This polymorphism has been 
repeatedly shown to associate with insulin sensitivity, but the specific insulin-sensitizing 
mechanisms have remained unclear. Furthermore, we lack knowledge of the effects that 
genetic variation in PPAR genes may have on insulin sensitivity at the whole body and 
tissue-specific level.  
This study assessed the effect of SNPs in PPAR genes on insulin sensitivity. The glucose 
clamp technique and [18F]-fluorodeoxyglucose and positron emission tomography were 
used to measure the rates of whole body, skeletal muscle, subcutaneous adipose tissue, and 
hepatic glucose uptake during insulin stimulation. Both non-diabetic and diabetic subjects 
were studied. 
Non-diabetic, non-obese subjects carrying the Ala12 allele of the Pro12Ala 
polymorphism (n=21) had higher rates of whole body (WBGU) and skeletal muscle glucose 
uptake (SMGU) than subjects with the Pro12Pro genotype (n=51), while no difference in 
adipose tissue glucose uptake (SFGU) was found. In obese subjects (n=52) there were no 
differences in WBGU, SMGU or SFGU according to the Pro12Ala polymorphism implying 
that the insulin-sensitizing effect of the Pro12Ala polymorphism depends on obesity. In 
addition, in a group of obese subjects with T2DM carrying the Ala12 allele (n=18) we found 
a significantly higher hepatic glucose uptake (HGU) during insulin stimulation than in 
those with the Pro12Pro genotype (n=60), while in non-diabetic obese carriers of the Ala12 
allele the somewhat higher HGU observed did not reach statistical significance.  No 
differences according to the Pro12Ala polymorphism in HGU were found in either non-
obese non-diabetic (n=38) or diabetic subjects (n=27), indicating that the effect of this 
polymorphism on HGU is also dependent on obesity.  
Also, this study shows that SNPs in the PPARδ gene (PPARD) and their haplotypes were 
associated with WBGU and SMGU signifying that genetic variants in PPARD may regulate 
insulin sensitivity. Finally, a weak association of two SNPs in the PPARα gene (PPARA) on 
whole body and skeletal muscle insulin sensitivity was discovered, suggesting that also 
genetic variants of PPARA could affect insulin sensitivity. 
Collectively these results show that SNPs in the PPAR genes affect insulin action on 
glucose metabolism at the whole body and tissue-specific level and may be involved in the 
development of insulin resistance. 
 
National Library of Medical Classification: QU500, WK 810, WK 820, WN 206 
Medical Subject Headings: Insulin Resistance; Peroxisome Proliferator-Activated Receptors; Positron-
Emission Tomography; Polymorphism, Single Nucleotide; Diabetes Mellitus, Type 2 
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TIIVISTELMÄ: 
Tyypin 2 diabeteksen (T2DM) patogeneesi on monitekijäinen ja osin tuntematon. Siihen 
kuuluu insuliiniresistenssi ja heikentynyt insuliinin eritys. Sekä ympäristö- että 
perintötekijät altistavat insuliiniresistenssille. Peroksisomiproliferaattoreilla aktivoituvat 
reseptorit (PPAR) ovat tumareseptoreja, jotka vaikuttavat moniin solujen toimintoihin 
kuten energia-aineenvaihduntaan. Yhden emäksen monimuotoisuus (SNP) PPARγ-
geenissä aiheuttaa Pro12Ala-polymorfian. Tämän polymorfian on osoitettu liittyvän 
insuliiniherkkyyteen, mutta sen tarkat vaikutusmekanismit ovat selvittämättä. Emme 
myöskään tiedä sitä, kuinka perintötekijävaihtelu PPAR-geeneissä vaikuttaa 
insuliiniherkkyyteen koko kehon ja eri kudosten tasolla.  
Tässä tutkimuksessa selvitettiin, miten PPAR-geeneissä esiintyvät SNPt vaikuttavat 
insuliiniherkkyyteen. Eri kudosten (lihas, ihonalaisrasva, maksa) sokerin soluunotto 
mitattiin insuliinistimulaation aikana käyttäen positroniemissiokuvausta yhdessä [18F]-
fluorodeoksiglukoosin kanssa ja koko kehon sokerin soluunotto määritettiin clamp-
tekniikalla. Tutkimuksessa oli mukana sekä T2DM sairastamattomia että sairastavia 
henkilöitä.  
Laihoilla, T2DM sairastamattomilla henkilöillä, joilla oli Ala12 alleeli, todettiin suurempi 
lihaksen (SMGU) ja koko kehon (WBGU) sokerin soluunotto kuin niillä, joilla oli Pro12Pro-
genotyyppi. Sen sijaan rasvakudoksen (SFGU) sokerin soluunotto ei eronnut Ala12 alleelin 
kantajien ja Pro12Pro-genotyypin omaavien välillä. Vastaavia eroja ei myöskään havaittu 
lihavien ryhmässä osoittaen, että tämän polymorfian vaikutus riippuu lihavuudesta. 
Lisäksi lihavilla T2DM sairastavilla, joilla oli Ala12 alleeli, havaitsimme suuremman 
sokerin soluunoton maksassa (HGU) verrattuna niihin, joilla oli Pro12Pro-genotyyppi. 
Myös T2DM sairastamattomilla, lihavilla henkilöillä, joilla oli Ala12 alleeli, oli jonkin verran 
suurempi HGU kuin Pro12Pro-genotyypin omaavilla henkilöillä, mutta tämä tulos ei ollut 
tilastollisesti merkitsevä. Muilla sekä T2DM sairastamattomilla että sairastavilla henkilöillä 
ei todettu eroa HGUssa suhteessa Pro12Ala polymorfiaan, viitaten siihen, että myös 
maksassa Pro12Ala polymorfian vaikutus sokerin soluunottoon riippuu lihavuudesta.  
Lisäksi tämä tutkimus osoittaa, että SNPt PPARδ-geenissä (PPARD) ja niiden 
haplotyypit näyttävät vaikuttavan sokerin soluunottoon lihaksessa ja koko kehon tasolla, 
osoittaen että myös SNPt PPARDssa saattavat säädellä insuliiniherkkyyttä. Lopuksi, 
tutkimuksessa havaittiin myös heikko yhteys PPARα-geenin (PPARA) yhden emäksen 
vaihtelun ja lihaksen sekä koko kehon insuliiniherkkyyden välillä, osoittaen että muutokset 
myös PPARAssa voivat vaikuttaa insuliiniherkkyyteen.  
Kaiken kaikkiaan tämä tutkimus osoittaa, että perintötekijävaihtelu PPAR-geeneissä 
vaikuttaa insuliinin toimintaan sokeriaineenvaihdunnassa koko kehon ja eri kudosten 
tasolla, ja nämä geenimuutokset saattavat vaikuttaa insuliiniresistenssin kehittymiseen. 
 
Yleinen suomalainen asiasanasto: insuliiniresistenssi; reseptorit; positroniemissiotomografia; aikuistyypin 
diabetes; geenit 
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1 Introduction 
Insulin is a key regulator of human energy metabolism and its reduced action in target 
organs is called insulin resistance. Insulin resistance plays a crucial role in the pathogenesis 
of type 2 diabetes mellitus (T2DM), prediabetic states, and cardiovascular disease (1).  
Environmental and genetic factors and their interactions are determinants of insulin 
resistance. Major environmental risk factors for obesity, T2DM and insulin resistance 
include physical inactivity, positive energy balance and diet composition. Generally, insulin 
resistance has been assessed at the whole body level, but recent technological advances 
have made it possible to investigate insulin resistance at the tissue-specific level. Animal 
models have introduced several different insulin resistance phenotypes depending on the 
insulin resistant tissue. Moreover, biological imaging applying positron emission 
tomography (PET) and [18F]-fluorodeoxyglucose (FDG) have enabled studies of the effects 
of insulin on glucose uptake in target tissues in vivo in humans. These methods have 
increased our understanding of the roles that different insulin’s target tissues play in 
insulin resistance. 
Although the vigorous search for genetic predictors of T2DM by linkage analysis, the 
candidate gene approach and genome-wide association has thus far revealed several loci, 
they are estimated to explain only a minority of the total heritability of T2DM and related 
states (2, 3). Moreover, only a few of the known genetic variants predisposing to T2DM are 
implicated in insulin resistance. Therefore, further studies are needed to increase our 
knowledge about the genetic determinants of insulin resistance. 
The peroxisome proliferator-activated receptors (PPARs) are nuclear receptors involved 
in lipid and glucose metabolism as well as immunologic and inflammatory regulation. The 
three members of the PPAR subfamily (PPARα, -β/δ, and -γ) have distinctive and diverse 
roles in the metabolic regulation of energy homeostasis. A relatively common single 
nucleotide polymorphism (SNP) in the PPARγ gene, the Pro12Ala polymorphism, is 
associated with insulin resistance and T2DM. However, the insulin-sensitizing effect of this 
polymorphism at the tissue level has not been previously characterized. Furthermore, we 
lack knowledge on the effects of other genetic variants in the PPAR genes on insulin 
sensitivity.  
In the present study, the impact of SNPs in the PPAR genes on insulin sensitivity at the 
whole body and tissue level was investigated by combining the candidate gene approach 
and the assessment of insulin sensitivity with the glucose clamp and  [18F]FDG-PET. In 
addition to a thorough description of the subjects, methods, and results of the current 
study, the following pages will also summarize the scientific literature on insulin resistance, 
the measurement of insulin sensitivity, insulin signaling and action in different insulin 
sensitive tissues, and the role of PPARs in glucose and lipid metabolism.  
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2 Review of the literature 
2.1 INSULIN RESISTANCE 
2.1.1 Definition 
Insulin, a peptide hormone secreted by the pancreatic β-cells, has a variety of biological 
effects in several target tissues. The reduced ability of insulin’s target tissues to respond to 
insulin is called insulin resistance, a key feature in the pathogenesis of type 2 diabetes 
mellitus (T2DM) (4). Insulin sensitivity is defined in terms of insulin concentration required 
to cause half of its maximal effect on glucose uptake (5). Thus, an increase in insulin 
sensitivity refers to a decrease in the insulin concentration needed to cause 50% of its 
maximal effect on glucose transport (6). This definition is problematic as it takes into 
account only insulin’s effect on glucose uptake, ignoring important functions including the 
suppression of gluconeogenesis and lipolysis. In spite of that, current methods for 
measuring insulin sensitivity are primarily based on insulin’s action on glucose disposal 
(5). 
Hyperglycemia develops as insulin secretion fails to overcome the falling insulin 
response in its target tissues. The current epidemic of T2DM parallels a rise in the 
prevalence of obesity and insulin resistance. It is estimated that around 7% of adults 
worldwide are affected by T2DM and this number is estimated to rise to 9% by 2030 
(International Diabetes Federation 2011; www.idf.org, accessed 2012/03/10). Although 
initially increased pancreatic insulin secretion can compensate for defective insulin action, 
insulin resistance per se is a strong predictor of both T2DM (7) and cardiovascular disease 
(8). In fact, insulin resistance is observed over a decade before overt T2DM develops in 
subjects with family history of diabetes (7).  
Insulin resistance commonly coexists with other components of the so-called metabolic 
syndrome (formerly insulin resistance syndrome or syndrome X), including general and 
visceral obesity, hepatic steatosis, low-grade inflammation, hypertension, dyslipidemia, 
and hyperuricemia (9), placing insulin resistance in a central position as a cardiovascular 
hazard. Accordingly, T2DM is associated with high rates of morbidity and premature 
mortality, mostly due to cardiovascular diseases (10).  Insulin resistance is tightly linked 
with obesity, T2DM, hypertension, dyslipidemia and coronary artery disease (1). The 
current epidemic of T2DM and insulin resistance creates a substantial economical burden in 
addition to excessive individual suffering, highlighting the need for further understanding 
of the predisposing factors. 
2.1.2 Risk factors for insulin resistance and T2DM 
Environmental risk factors. Both environmental and genetic risk factors predispose to 
insulin resistance and T2DM (11). Environmental factors promoting insulin resistance and 
T2DM include sedentary lifestyle (insufficient energy expenditure), chronic excessive 
energy intake, obesity and diet composition, with high saturated/unsaturated fat intake 
ratio and low intake of fiber particularly promoting insulin resistance (12).  Consumption of 
carbohydrates and coffee has been repeatedly linked with improved insulin sensitivity (13-
15). Also many drugs influence insulin sensitivity, including glucocorticoids (16), growth 
hormone (17) and nicotinic acid (18). The importance of obesity as a risk factor for T2DM is 
underscored by the very high concordance rates between obesity and insulin resistance. 
The prevalence of insulin resistance is around 10% in lean versus 60% in extremely obese 
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subjects (19). Body fat distribution, particularly abdominal obesity, seems to play an even 
more significant role than obesity per se as a predictor of insulin sensitivity (20).  
Both high and low birth weight increase the lifetime risk for obesity and T2DM. In 
addition, rapid postnatal “catch-up” growth has been shown to predispose to insulin 
resistance and T2DM in adulthood (21-23). The thrifty phenotype hypothesis suggests that 
insufficient nutrient supply during fetal life leads to insulin resistance, impaired glucose 
tolerance and T2DM later in life (21, 24, 25). Adaptive mechanisms set up during nutrient 
deficiency in fetal life to conserve energy would eventually turn out to be harmful in the 
context of energy overload. Individuals born small who later in life develop obesity are at 
greatest risk for insulin resistance and T2DM (26, 27). However, the thrifty phenotype can 
also be seen as a fetal phenotype for thrifty genes (22, 28).  
Advancing age has been considered to predispose to T2DM, but the association of 
insulin resistance and age may be more related to underlying physical inactivity and 
obesity or adiposity and a loss of muscle mass (29).  
Genetic risk factors. Both T2DM and insulin resistance have a genetic background. In 
monozygotic twins the concordance of T2DM is considerably higher than in dizygotic twins 
(30, 31). Also the risk of T2DM is clearly elevated in offspring of patients with T2DM (32), 
and insulin resistance is present from childhood to adulthood in these high risk subjects 
even before they develop T2DM (33, 34). While decreasing insulin sensitivity predicts the 
development of T2DM in individuals with a family history of T2DM (7), this is not the case 
in subjects without family history of T2DM (35), suggesting that genetic factors play an 
important role especially in insulin resistance. Ethnic differences in the prevalence of 
insulin resistance and T2DM argue for a hereditable factor predisposing to these conditions 
(36, 37).  There may also be gender differences in the heritability of T2DM (38). 
Furthermore, several studies have already identified roughly 40 genetic variants that 
contribute to the risk of T2DM (39). Given this evidence, genetic factors are implicated in 
the development of T2DM, in addition to lifestyle and environmental factors (11). 
2.1.3 Measurement of insulin sensitivity 
Several methods of measuring insulin sensitivity have been described, Table 2.1 (5, 40). 
These methods yield results that are fairly well correlated, even though some assess insulin 
sensitivity during fasting and others after an intervention (oral and intravenous glucose 
tolerance tests, insulin clamp technique). Common for all these conventional methods is 
that they measure insulin sensitivity at the whole body level. Although in vitro several 
aspects of insulin function can be directly measured at the cellular level, assessment of 
tissue-specific insulin sensitivity in vivo has been more laborious (involving e.g. 
microdialysis techniques or arteriovenous glucose gradient methods) (41). The use of 
radioactive tracers in combination with positron emission tomography (PET) allows 
accurate, non-invasive measurement of tissue-specific tracer uptake. These methods can be 
applied to determine tissue-specific glucose uptake in vivo using 18F-labeled 
fluorodeoxyglucose ([18F]FDG) as a tracer for glucose (42-44). 
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Measurement of whole body insulin sensitivity. Hyperinsulinemic euglycemic clamp 
technique. Commonly regarded as the gold standard method for measuring insulin 
sensitivity, the hyperinsulinemic euglycemic clamp involves the infusion of a dose of 
insulin adjusted for body weight or surface area at a standard rate and a simultaneous 
infusion of glucose at a variable rate to maintain euglycemia (45). Different insulin infusion 
rates can be used and full dose-response curves can be generated. After the steady state has 
been achieved, the whole body insulin stimulated glucose uptake is comparable to the 
glucose infusion rate, because infused glucose and insulin effectively shut down 
endogenous glucose production.  
The experimental complexity and high costs are the main downsides of the 
hyperinsulinemic euglycemic clamp method. Other disadvantages include the use of 
insulin at high physiological or even supraphysiological levels as compared to basal 
conditions, and the peripheral insulin infusion, which reverses the normal gradient 
between portal and peripheral insulin level (5, 57). Also, the clamp approach estimates the 
effect of insulin on whole body glucose disposal, failing to capture other aspects of insulin’s 
metabolic effects.  
In practice however, the hyperinsulinemic euglycemic clamp provides a good 
discrimination between subjects with normal insulin sensitivity and those with insulin 
resistance (19) and prevails as a reference method for measuring individual differences in 
insulin sensitivity (5). It can also be used to assess insulin sensitivity in subjects with type 1 
diabetes mellitus and other states of defective endogenous insulin secretion. In addition, 
radiolabeled glucose tracers can be used during the clamp to simultaneously measure 
hepatic glucose production (58) and tissue-specific glucose uptake (42).  
Insulin suppression test. Another direct method for measuring insulin sensitivity is the 
insulin suppression test (46). This method involves the infusion of somatostatin or its 
analog (octreotide) to suppress endogenous insulin and glucagon secretion. Thereafter both 
insulin and glucose are infused at constant rates. Once the steady state has been reached, 
circulating insulin and glucose levels are determined. Insulin sensitivity is directly 
proportional to the prevailing blood glucose level with high glucose levels indicating 
insulin resistance (5). The results of this insulin suppression test correlate generally well 
with the results of the hyperinsulinemic euglycemic clamp (59, 60). 
Intravenous glucose tolerance test. Insulin sensitivity can be measured indirectly 
simultaneously with the assessment of insulin secretion by an intravenous glucose 
tolerance test (IVGTT). A glucose bolus of 300 mg/kg is given intravenously and blood 
samples for the measurement of glucose, insulin and C-peptide are taken repeatedly. 
Insulin sensitivity index can be calculated by the Minimal Model (47). This index has been 
validated against the glucose clamp technique (61). Although the Minimal Model is 
somewhat laborious, it is simpler than the glucose clamp. However, some concern has been 
raised about the reliability of the Minimal Model, and consequently the initial protocol has 
been modified to improve the precision of parameter estimation (48). Although several 
assumptions are needed for the Minimal Model, it is a useful method for estimating 
simultaneously insulin sensitivity and insulin secretion (40). An IVGTT is dependent on 
endogenous insulin secretion and therefore cannot be used in subjects with type 1 diabetes 
mellitus.  
Oral glucose tolerance test. Both the hyperinsulinemic euglycemic clamp and the IVGTT 
can be criticized of being unphysiological, as glucose is administered peripherally as 
opposed to the physiological oral route. The oral glucose tolerance test (OGTT) (75g oral 
glucose load or standard meal) (49) can be regarded as a more physiological method for 
estimating insulin sensitivity, and it is the only method to discriminate glucose tolerance 
from insulin sensitivity. However, it is unfeasible for subjects without endogenous insulin 
secretion. In addition to insulin’s metabolic action, insulin secretion, the incretin effect, 
glucagon secretion, neurohumoral actions and other effects of glucose ingestion can be 
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evaluated by an OGTT. Glucose and insulin levels are measured before glucose ingestion 
and thereafter at 30-min intervals for two hours. Glucose and insulin measurements are 
used to estimate insulin sensitivity by mathematical models that have been validated 
against the glucose clamp (50-53). A clear advantage of these methods is the simplicity of 
the OGTT procedure, and thus they can be used also in large study populations. However, 
these methods are limited by considerable individual variation in gastric emptying, post-
absorptive glucose handling, and somewhat poor reproducibility (62). The insulin 
sensitivity indices derived by these calculations reflect the combined effect of peripheral 
and hepatic insulin sensitivity (5). 
Insulin sensitivity indices derived from fasting measurements. In large studies the 
hyperinsulinemic euglycemic clamp and OGTT are unfeasible, and therefore there is a need 
for simple and inexpensive estimates of insulin sensitivity. As fasting hyperinsulinemia 
correlates with insulin resistance in healthy subjects, a measure of fasting insulin can be 
used as an estimate of insulin sensitivity. This approach does not take into account 
impaired insulin secretion or variation in insulin clearance and therefore this measure gives 
erroneous results in the context of frank diabetes and impaired glucose tolerance (5, 62).  
Indices calculated on the basis of fasting insulin and glucose levels (Homeostasis Model 
Assessment (HOMA): Insulin x Glucose /22.5 for insulin resistance (HOMA-IR), 20 x 
Insulin/(Glucose-3.5) for β-cell function (HOMA-β%); HOMA-%S for insulin sensitivity can 
be estimated using HOMA-IR and HOMA-β%) (54) and Quantitative Insulin Sensitivity 
Check Index (QUICKI): 1/ (log insulin + log glucose)) (56) are attempts to overcome these 
limitations based on the principle that fasting hyperglycemia is a function of β-cell capacity 
and insulin resistance. Both HOMA and QUICKI are limited by poor accuracy and by the 
fact that results of fasting measurements are essentially determinants of hepatic insulin 
sensitivity (63). In an attempt to increase the reliability of these indices, both HOMA and 
QUICKI formulas have been revised (55, 64-66). Despite the improvements, these indices 
fail to discriminate between subtle differences in insulin sensitivity and thus can only be 
used in large population studies (62, 67). 
Measurement of tissue-specific insulin sensitivity. Microdialysis. Metabolism of 
different tissues can be assessed in vivo by microdialysis also in humans (68).  A neutral 
dialysis fluid is infused through custom dialysis membrane tubing at a steady rate into the 
target tissue. The outgoing dialysate reflects the composition of the interstitial space of the 
target tissue and can be analyzed for the target molecule such as glucose. If arterial glucose 
level and regional blood flow are determined, glucose extraction and glucose uptake rates 
can be estimated according to Fick’s principle (69). In addition, insulin’s effect on adipose 
tissue lipolysis can be estimated by microdialysis. Indeed, microdialysis has been 
successfully used to assess glucose and lipid metabolism in vivo in both skeletal muscle and 
adipose tissue (41, 43, 70-73). The limitations of this technique include invasiveness, high 
costs, inability to study hydrophobic (e.g. free fatty acid (FFA)) or large molecules, and the 
complex analytical techniques required (74). 
Arteriovenous difference technique (forearm technique). By measuring the arteriovenous 
glucose gradient across the target tissue, the regional rate of glucose uptake can be 
determined according to Fick’s principle if regional blood flow is known. This technique 
has been applied successfully in metabolic studies on skeletal muscle and adipose and 
splanchnic tissues (74-76). Also other metabolites, such as FFA, can be measured, allowing 
the assessment of insulin sensitivity of lipolysis, in addition to glucose uptake (77, 78). 
However, this technique is limited by sometimes problematic vein cannulation (74) and 
that the results could reflect regional metabolite extraction instead of actual tissue-specific 
uptake. 
Tracer methods for determining glucose fluxes in the liver. Hepatic insulin resistance is 
characterized by defective suppression of hepatic glucose production (HGP) by insulin. 
Most of endogenous glucose production (EGP) is derived from liver, with a lesser amount 
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arising from the kidneys (79). Due to technical difficulties in determining HGP, most 
studies have considered EGP as a measure of hepatic insulin sensitivity (80). Commonly, 
EGP has been measured by tracer-dilution methods with isotope labeled (e.g. 13C, 14C, 2H, 
3H) glucose molecules employed as tracers (81, 82). Assuming a steady state can be reached 
with tracer infusion, EGP can be calculated by dividing the tracer infusion rate by the ratio 
of plasma tracer and glucose concentrations (80). Several mathematical solutions can be 
applied to overcome problems arising from non-steady states, different tracer kinetics and 
study protocols (80).  
Hepatic, or more precisely, splanchnic tissue glucose uptake (SGU) can be determined by 
combining arteriovenous method and measurement of EGP. Net splanchnic glucose 
balance (SGB) reflects the product of two simultaneously ongoing processes, namely SGU 
and HGP. SGB can be estimated as the product of the arterial – hepatic venous blood 
glucose concentration difference and the hepatic blood flow. After the measurement of both 
SGB and HGP, SGU can be calculated simply by subtracting SGB from HGP (76). 
Alternatively, SGU can be calculated by the product of the splanchnic glucose extraction 
ratio (SER) and the delivery of glucose to the splanchnic tissues as follows: SGU = SER x 
splanchnic blood flow x arterial blood glucose concentration, where SER can be calculated 
from the arterial vs. hepatic vein difference of tracer concentration divided by the arterial 
tracer concentration (76). 
PET scanning in the assessment of insulin stimulated glucose uptake in target tissues. 
Injection of a short-lived radioactive positron emitting tracer followed by PET scanning 
allows the detection of tracer substance accumulation in target tissues in vivo (42). [18F]FDG 
can be used as a tracer when determining the rates of glucose uptake in different tissues 
including skeletal muscle (83), subcutaneous and visceral adipose tissue (43), and liver (84). 
A mathematical model of tracer kinetics is required for determining the rates of fractional 
tracer uptake. For [18F]FDG the three-compartment model by Sokoloff et al. (85) can be 
employed (86). The three [18F]FDG compartments include circulating blood, intracellular 
space and metabolized state. Of note, glucose and [18F]FDG differ only slightly in the 
transport between the blood and the intracellular space and phosphorylation. In contrast, 
kinetics differ because [18F]FDG is not dephosphorylated and thus becomes trapped in 
target tissues.  
The fractional [18F]FDG uptake rate (Ki) can be calculated using the three-compartmental 
model as: Ki = k1 x k3 / (k2 + k3), where K1 is the rate of tracer influx from blood to 
intracellular space, k2 is the rate of backflux and k3 is the rate of phosphorylation of 
[18F]FDG (87). Notably, k4=0 as [18F]FDG cannot be dephosphorylated and therefore cannot 
enter glycolysis (88). Another possibility for [18F]FDG uptake calculation is the use of a 
graphical approach by employing plasma and tissue time-activity curves by Patlak plotting, 
which is valid for irreversible tracers (89). The ratio between tissue and blood [18F]FDG 
concentration is plotted against the time-[18F]FDG-activity integral (t0-t1) of the arterialized 
blood divided by [18F]FDG concentration at time t1 (90). After the steady rate of tracer 
accumulation has been reached, the fractional tracer uptake rate Ki is equal to the slope of 
the curve gained.  
As [18F]FDG and glucose differ slightly in their transport and phosphorylation, a lumped 
constant (LC) is used to calculate the total glucose uptake rate by multiplying Ki by the 
prevailing steady-state blood glucose level and dividing the result by LC. Using 
microdialysis, LC for skeletal muscle has been shown to be 1.2 (91), for adipose tissue 1.14 
(43) and for liver 1.0 (44). The steady state requirement can be achieved by combining the 
[18F]FDG-PET with hyperinsulinemic euglycemic clamp. 
2.1.4 Methods to identify gene variants regulating insulin sensitivity 
Linkage studies identify gene regions in related subjects that occur in excess to that 
expected by independent inheritance (92). By linkage analysis chromosomal loci of interest 
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can be identified. This method has been particularly beneficial as a first-line genetic 
approach during analysis of an inherited disease or trait. Also rare genetic variants with 
large effects (monogenic diseases) can readily be identified by linkage analysis (93). 
However, the success rate for finding genetic predictors of complex polygenic diseases by 
linkage analysis has been low due to a low statistical power of this approach (92, 94). Only 
one susceptibility gene for T2DM, transcription factor 7 like 2 gene (TCF7L2), has been 
partially identified by linkage analysis (28). 
The rationale for candidate gene studies relies on the presumption that genetic variation 
behind the phenotype under investigation is caused by a variant in the candidate gene (95). 
Candidate genes are those with a known function in the presumed disease biology. This 
approach is economically advantageous since only the analysis of the target gene is 
required. The candidate gene approach can detect susceptible single nucleotide 
polymorphisms (SNPs) with quite small individual effects. However, the replication 
success of established association has been low, and the candidate gene approach does not 
cover information from the entire genome (96). Among the candidate genes studied for 
T2DM only the variants of the peroxisome proliferator-activated receptor-γ (PPARγ) gene 
(PPARG), potassium inwardly rectifying channel, subfamily J, member 11 (KCNJ11) and 
Wolfram syndrome-1 (WFS-1) genes have been replicated (28). 
Recent technological advances have made possible to genotype hundreds of thousands 
and even millions of SNPs in the entire genome in large population samples. Genome-wide 
association studies (GWAS) arising to identify gene variants for T2DM have been able to 
capture most of the variation in the genome. These studies have replicated the association 
of TCF7L2, PPARG, WSF-1, KCNJ11 with T2DM and introduced several previously 
unidentified susceptibility loci, some with currently unknown function in the pathogenesis 
of T2DM (97-104).  
The limitations of GWAS include the inability to offer biological explanations for the 
established associations, and to identify structural variants other than SNPs. Furthermore, 
the results cannot be generalized to risk prediction in different ethnic groups (2). The 
current T2DM susceptibility loci identified by GWAS explain only a small fraction of the 
total estimated hereditability (2, 3). So far, the risk loci for T2DM identified by GWAS have 
mainly included SNPs regulating insulin secretion, and only a few of the gene variants, e.g. 
in PPARG, have regulated insulin sensitivity (3, 28). 
2.2 GLUCOSE METABOLISM AND INSULIN SIGNALING 
2.2.1 Cellular glucose uptake 
Glucose is the most important source of energy for mammalian cells. Effective 
transportation of glucose through lipid cell membranes is imperative in the successful 
regulation of energy homeostasis. In addition to regulating cellular glucose uptake and 
metabolism, insulin controls lipid and protein metabolism and cellular pathways of growth 
and differentiation. 
 After a carbohydrate-containing meal, the blood glucose concentration rises and the 
glucose excess is transported into peripheral storage tissues (e.g. liver, skeletal muscle, 
heart and adipose tissue). Elevation of blood glucose induces insulin secretion from the 
pancreatic β-cells, and insulin accelerates glucose uptake in peripheral tissues. The majority 
(~75%) of insulin-stimulated glucose uptake occurs in skeletal muscle (76). Glucose enters 
the cells via a family of facilitative glucose transporters (GLUTs). Most of the insulin-
dependent glucose uptake is mediated by GLUT4, primarily expressed in insulin-
responsive tissues such as striated muscle and adipose tissue. In contrast, the insulin-
independent GLUT2 is the primary operator in hepatic glucose uptake. After 
transmembrane transport glucose is phosphorylated into glucose-6-phosphate (G6P) by 
hexokinases. G6P is converted to uridine-5’-diphosphate-glucose and subsequently 
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polymerized by glycogen synthase (GS) to form glycogen, the storage-form of glucose. 
Alternatively, G6P can undergo dephosphorylation to glucose or glycolysis to form 
puryvate.  
Insulin promotes glucose uptake predominantly by stimulating the translocation of 
GLUT4 from intracellular vesicles to the cell membrane (exocytosis) and partially by 
inhibiting GLUT4 endocytosis from the cell membrane (105). Insulin exerts its biological 
functions largely through the insulin signaling cascade (Figure 2.1). Dysfunction of a 
number of the effectors in this pathway can predispose to insulin resistance (106-108).  
Insulin binds to the insulin receptor (IR) at the cell surface. IR consists of two 
extracellular α-units that bind insulin and two transmembrane β-units that possess tyrosine 
kinase activity. Insulin binding activates IR and leads to phosphorylation of tyrosine 
residues of intracellular substrates, including the most specific proteins for insulin 
signaling, insulin receptor substrate (IRS) proteins 1-4 (109).  
After activation the IRS proteins bind several other proteins mostly harboring Src 
homology 2 (SH2) domain (107,110), and stimulate two major pathways; the 
phosphaditylinositol-3 (PI-3) –kinase (PI3K) pathway, which is responsible for most of the 
metabolic actions of insulin, and the Ras-mitogen-activated protein kinase (Ras-MAPK) 
pathway, which is more important in mediating insulin’s action on cell growth and 
differentiation (Figure 2.1). It should be noted that different IRS isoforms may stimulate 
different intracellular pathways. For example, in skeletal muscle IRS1 is more involved in 
the PI3K pathway signaling and glucose uptake, whereas IRS2 is preferentially involved in 
Ras-MAPK activation (111). Also, in the liver IRS1 seems to regulate gene expression 
involved in gluconeogenesis, whereas IRS2 regulates genes controlling lipogenesis (112). 
Accordingly, different IRS isoforms seem to play divergent roles in metabolic control in 
different tissues (107). 
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Figure 2.1 Simplified representation of different pathways of insulin signaling (108). See text for 
detailed explanation. I; Insulin. 
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2.2.2 Insulin signaling pathways 
The PI-3 -kinase pathway. The PI3K has a regulatory subunit (p50, p55, p85) and a catalytic 
subunit (p110), each of which occurs in several isoforms (113). These isoforms have a 
different tissue distribution and unique functions (107). IRS proteins interact with the SH2 
containing regulatory subunit of PI3K and activate the catalytic unit to produce 
phosphaditylinositoltriphosphate (PIP3) from phosphaditylinositoldiphosphate (PIP2). 
Inhibition of the PI3K has been shown to result in reduced GLUT4 mediated glucose uptake 
in skeletal muscle (114). The regulatory subunit of PI3K can also act as negative regulator of 
PI3K and insulin action (107). PIP3 binds 3-phosphoinositide-dependent protein kinase-1 
(PDK-1), which activates the serine/threonine kinase Akt (aka protein kinase B (PKB)). 
Activated Akt 1) increases glycogen synthesis by phosphorylating glycogen synthase 
kinase-3 (GSK-3), an inhibitor of glycogen synthesis, 2) regulates GLUT4 translocation from 
storage vesicles to cell membrane via inhibition of Akt substrate of 160 kDa (AS160) 3) 
regulates protein synthesis by activating mammalian target of rapamycin (mTOR) 
pathway, 4) controls the expression of gluconeogenic and lipogenic enzymes by targeting 
forkhead box protein (FOX) family of transcription factors (107), and 5) inhibits lipolysis by 
activating  phosphodiesterase-3B (PDE-3B). Activation of the PI3K pathway seems to be 
necessary, but not sufficient per se to mediate insulin’s stimulatory action on glucose uptake 
(115). Skeletal muscle from subjects with T2DM is characterized by impaired PI3K and IRS1 
activation (116). 
The Ras-MAPK pathway. After activation of an IRS protein, the growth factor receptor 
binding protein-2 (Grb-2) - Son of Sevenless (SOS) complex, and subsequently Ras are 
recruited, followed by the activation of Ras (Figure 2.1). Ras proteins form a large family of 
small guanosine triphosphatases (GTPases) (117). Activated Ras recruits several 
downstream agents including PI3K and Raf kinase (118). MAPK family consists of several 
subfamilies with a common activation pattern. (119). One of these pathways involves Raf as 
MAPKKK, MEK as MAPKK, and extracellular signal-regulated kinase (ERK) as MAPK 
(120). The Ras-MAPK pathway controls the transcription genes involved in cell growth, 
survival, differentiation and adipogenesis. It is also involved in the negative feed-back loop 
of insulin signaling (107).  
Of importance, the Ras-MAPK pathway can be activated also directly without the 
involvement of IRS proteins; the phosphorylated IR can interact directly with an adapter 
protein Shc, which is able to interact with the Grb-2 – SOS complex and signal through the 
MAPK pathway. It is noteworthy, that insulin signaling through the Ras-MAPK pathway 
remains functional in insulin resistance of the PI3K pathway and contributes to the 
impaired lipid metabolism and accelerated rate of cardiovascular disease by promoting 
proliferation of smooth muscle cells and production of inflammatory mediators. 
Insulin signaling in lipid rafts. In addition to signaling through the PI3K and Ras-
MAPK pathways, activation of IR can also set off another signaling pathway mediated by 
the activation of the adapter protein APS (Figure 2.1) (121). IRs that activate this pathway 
are located in specialized areas of the cell membrane, so-called lipid rafts (122). This 
pathway includes the activation of proto-oncogenes c-CBL and CBL-b, CBL-associated 
protein (CAP), and small G-proteins TC10α and TC10β, ultimately promoting GLUT4 
translocation and glucose uptake through exhaustive protein activation cascades.  
2.3 INSULIN ACTION IN DIFFERENT TISSUES  
Although insulin resistance is commonly considered at the whole body level, probably due 
to the conventional measurement of insulin sensitivity by the glucose clamp technique, 
insulin has several target tissues, and defects in its action can therefore result in a variety of 
distinct phenotypes or insulin resistance syndromes (123), underscoring the need for 
knowledge of the mechanisms of tissue-specific insulin sensitivity. The tissue-specific 
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actions of insulin are highlighted by the targeted IR-knockout mice models that have shed 
light into the contribution of each insulin sensitive tissue to the pathogenesis of insulin 
resistance syndromes (124). 
2.3.1 Insulin receptor knockout mice 
Total ablation of IRs in mice leads to severe hyperinsulinemia, β-cell failure, and death due 
to diabetic ketoacidosis soon after birth due to the lack of insulin signaling and 
heterozygous IR+/- mice are characterized by a 60% decrease in the number of IRs in insulin 
sensitive tissues, and show moderate insulin resistance and β-cell hyperplasia despite being 
mostly glucose tolerant (125).  
Muscle IR knockout (MIRKO) mice demonstrate decreased insulin stimulated glucose 
uptake and insulin signaling in skeletal muscle without systemic insulin resistance (126).  
To maintain insulin sensitivity MIRKO mice seem to have an increased adipose tissue 
glucose uptake that leads to increased adiposity and metabolic syndrome. Importantly, 
MIRKO mice do not develop hyperinsulinemia, suggesting that muscle insulin resistance 
and increased adiposity are not sufficient by themselves to cause this pathological feature 
of T2DM (126). 
Liver IR knockout mice (LIRKO) exhibit mild hyperglycemia during fasting and become 
more hyperglycemic postprandially (127), due to the reduced insulin suppression of 
hepatic glucose production (128). LIRKO mice are also severely hyperinsulinemic because 
of compensatory hypersecretion of insulin from pancreatic β-cells, which undergo 
hypertrophy (127). Prevailing hyperinsulinemia promotes insulin resistance in other target 
tissues. 
Adipose tissue IR knockout mice (FIRKO) are characterized by reduced fat mass, normal 
glucose tolerance and fasting glucose level, reduced plasma insulin level, and protection 
from age and over-eating related deterioration of insulin sensitivity (129). 
Pancreatic β-cell IR null mice (β-IRKO) portray abnormal glucose tolerance, due to 
defective first phase insulin secretion after a glucose load, and reduced size of β-cells (130). 
These findings indicate that insulin regulates its own secretion by β-cells and pancreatic 
insulin resistance may contribute to the impaired insulin secretion associated with T2DM. 
The central nervous system (CNS) IR knockout mouse model (NIRKO) highlights the 
role of the CNS in glucose metabolism (131). IRs are widely expressed in the CNS especially 
in the hypothalamus and the pituitary gland. NIRKO mice show increased food intake and 
as a consequence obesity and insulin resistance (131).  
2.3.2 Skeletal muscle and insulin sensitivity 
Impaired glucose metabolism in skeletal muscle insulin resistance. Insulin resistance in 
skeletal muscle can manifest itself at several critical stages of glucose handling including 
glucose uptake, glycogen synthesis, and glucose oxidation. Insulin stimulates glucose 
uptake into skeletal muscle cells via GLUT4. Skeletal muscle glucose uptake accounts for 
the vast majority of the total whole body glucose disposal under euglycemic 
hyperinsulinemia. Insulin resistance in skeletal muscle is an early finding in the 
development of T2DM. PET studies have provided further evidence of impaired skeletal 
muscle glucose uptake in subjects with insulin resistance and T2DM (132, 133) indicating 
that IRS1, Akt, and atypical protein kinase C (aPKC) activity are diminished in T2DM, 
obesity and insulin resistance (134-138). In addition to alterations in the PI3K pathway, 
changes in the Ras-MAPK pathway of insulin signaling involving MAPK kinase family 
have been demonstrated in insulin resistant states in skeletal muscle (134, 139, 140).  
Cytokines (e.g. TNFα and resistin) secreted from adipose tissue also impair insulin-
stimulated glucose uptake in skeletal muscle (141-145), whereas other adipose tissue 
derived factors (e.g. adiponectin and leptin) can improve glucose metabolism in skeletal 
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muscle by activating fatty acid oxidation (reducing lipotoxicity) through adenosine 
monophosphate activated kinase (AMPK) -dependent pathways (146). 
Defects in glycogen synthesis have also been observed in patients with T2DM, in their 
offspring and in subjects with impaired glucose tolerance. Skeletal muscle glycogen 
synthesis represents the primary pathway for non-oxidative glucose disposal (147). In 
addition to glucose transport into muscle cells, glycogen synthesis involves the 
phosphorylation of glucose to G6P by hexokinase, and the final polymerization to glycogen 
by GS. Each of these steps has been reported to be defective in patients with T2DM, but the 
rate-limiting defect appears to be the uptake and transport of glucose into muscle cells 
(148). Besides stimulating glucose uptake, insulin promotes glycogen synthesis by 
activating protein phosphatase -1 (PP-1), which directly activates GS and also deactivates 
GSK-3, an inhibitor of GS (106) (Figure 2.1). Although glycogen synthesis is impaired in 
insulin resistant states, it seems that defective muscle glycogen synthesis cannot per se cause 
insulin resistance (149). In contrast, it represents the consequence of insulin resistance (150). 
Impaired lipid metabolism in skeletal muscle insulin resistance. Both T2DM and 
obesity-related insulin resistance are associated with elevated levels of plasma non-
esterified (free) fatty acids (FFAs). Elevation of plasma FFA levels during insulin 
stimulation has been shown to reduce skeletal muscle glucose uptake of healthy 
individuals to a level comparable with T2DM. This is due to diminished glucose transport 
activity (151) resulting from the reduced IRS1 associated PI3K activity as a consequence of 
FFA metabolite stimulation of PKC-θ resulting in a 50% decrease of PI3K activity (152). The 
uptake of FFA into skeletal muscle is increased and FFA oxidation decreased in insulin 
resistance. Intracellular pile-up of FFA metabolites like diacylglycerol, fatty acyl-CoA, and 
ceramide has been hypothesized to lead to reduced skeletal muscle glucose uptake (153). 
This deterioration in insulin sensitivity due to lipid metabolite accumulation in non-adipose 
tissues is called lipotoxicity. Indeed, the skeletal muscle lipid content is inversely correlated 
with insulin sensitivity (154). 
“Metabolic flexibility” in skeletal muscle. “Metabolic flexibility” is the capacity of the 
organism to adapt fuel oxidation to fuel availability (155). Skeletal muscle can use both 
glucose and fatty acids for energy production. Initially it was proposed that the increased 
availability of FFA would lead to the preference of fatty acid oxidation over glucose 
oxidation in skeletal muscle resulting in reduced glucose uptake and insulin resistance 
(156). In contrast, muscle glucose oxidation has been found to be increased in subjects with 
T2DM and in obesity (157), despite of the increased availability of FFAs in these conditions, 
suggesting that reduced fatty acid oxidation and consequent lipotoxicity could be the 
primary cause of insulin resistance in skeletal muscle. Accordingly, increased skeletal 
muscle glucose metabolism leads to increased intracellular malonyl-CoA accumulation, 
which readily inhibits carnitine palmitoyl transferase (CPT)-1 thereby blocking the entry of 
FFA into mitochondria for oxidation (158). Overexpression of CPT-1 has been shown to 
increase FFA oxidation and reduce lipotoxicity (159, 160). Consequently, it has been 
hypothesized that the metabolic switch between fatty acid and glucose oxidation is flawed 
in insulin resistant states (161). 
According to this hypothesis, a “metabolically flexible” insulin sensitive subject would 
have a preference of FFA oxidation during fasting and a prompt switch to carbohydrate 
oxidation during insulin stimulation, with blunted fasting FFA oxidation and insulin-
stimulated glucose oxidation observed in “metabolically inflexible” insulin resistant 
subjects. This is supported by the higher fat oxidation capacity found in the context of 
insulin sensitivity, leanness, and aerobic fitness (162). However, the concept and 
determinants of metabolic flexibility and its role in the pathogenesis of insulin resistance 
and T2DM need further characterization (155).  
Mitochondrial dysfunction and oxidative phosphorylation. Glucose and lipid 
oxidation in skeletal muscle takes place in the mitochondria, where adenosine diphosphate 
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(ADP) is converted to adenosine triphosphate (ATP) by oxidative phosphorylation 
(OXPHOS). Differences in mitochondrial number, density, morphology and function  have 
been observed in skeletal muscle in obese subjects, subjects with T2DM, and in insulin 
resistant offspring of subjects with T2DM (163-169). In addition, insulin resistant muscle is 
characterized by a reduced number of oxidative (type 1) muscle fibers and an increased 
amount of nonoxidative, less insulin sensitive (type 2) muscle fibers (167, 170, 171), and a 
diminished activity of enzymes involved in OXPHOS. Furthermore, the capacity for 
OXPHOS in skeletal muscle has been reported to be 30% lower in insulin resistant subjects 
than in normal individuals (172). 
Insulin has been shown to increase skeletal muscle oxidative capacity and increase the 
transcription of genes encoding mitochondrial proteins (173), while decreased expression of 
OXPHOS genes associates with insulin resistance and T2DM (174). In fact, most of the 
OXPHOS genes seem to be regulated in a coordinated fashion (175). Importantly, the 
expression of OXPHOS genes is regulated by peroxisome proliferator-activated receptor γ 
co-activator 1α (PGC-1α), a cold-inducible transcription factor controlling thermogenesis, 
mitochondrial biogenesis and skeletal muscle fiber type switching (176, 177). PGC-1α has 
been associated with several components of T2DM and insulin resistance (178).  
Additionally, physical activity and coffee or caffeine consumption are associated with 
increased OXPHOS and with a reduced risk for T2DM (6, 14, 179, 180). 
These studies suggest that mitochondria and OXPHOS may play a role in the 
development of insulin resistance (181). On the other hand, some studies suggest that 
mitochondrial dysfunction is not a cause, but rather a marker or consequence of insulin 
resistance (182). 
2.3.3 Adipose tissue and insulin sensitivity 
Although adipose tissue accounts for only a small proportion of whole body insulin 
stimulated glucose uptake, it has a fundamental role in the regulation of insulin sensitivity. 
Adipose tissue controls energy metabolism by storing and releasing FFAs, glucose and 
glycerol, and by secreting adipose tissue derived cytokines (adipokines), several of which 
have been implicated in the regulation of insulin sensitivity (183). Both excess and lack of 
adipose tissue can lead to insulin resistance (184). Not only the amount of fat, but also the 
distribution of fat contributes to insulin sensitivity (185).  
Insulin stimulates energy storage in adipose tissue by facilitating glucose and FFA 
uptake, inhibiting lipolysis, and stimulating de novo fatty acid synthesis in adipocytes. 
Insulin also exerts adipose tissue growth and differentiation and may control the 
expression of adipokines (186). On the other hand, insulin resistance in adipose tissue 
results in reduced uptake of glucose and FFAs as well as reduced postprandial suppression 
of fatty acid and glycerol release from adipose tissue, which leads to increased FFA flux to 
other organs such as liver, skeletal muscle, and pancreas, and predisposes to lipotoxicity in 
these tissues (187). Therefore, improved capacity of adipose tissue to store lipids can protect 
from lipotoxicity. 
The role of different fat depots. The distribution of adipose tissue seems to be a more 
important determinant of insulin action than the total amount of fat. In particular, visceral 
adipose tissue is characterized by higher activity of lipolysis and lower insulin sensitivity. 
Of importance, FFAs from visceral adipose depots drain directly into the portal vein and 
liver and effectively reduce hepatic glucose uptake and increase glucose production, 
placing visceral fat in a central position in the regulation of hepatic insulin sensitivity (188). 
Although most of systemic FFA release during fasting and under insulin stimulation arises 
from non-visceral adipose tissue depots, hepatic FFA delivery is in greater proportion 
determined by visceral fat lipolysis in subjects with visceral obesity (189). Visceral fat is also 
associated with inflammatory markers (190-192) and altered adipocytokine secretion (193). 
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Visceral fat mass seems to be a key determinant of metabolic abnormalities and insulin 
resistance in subjects at high risk for T2DM (20). 
Recently, PET studies have confirmed the presence of functional brown adipose tissue in 
adults (194). Brown adipose tissue is involved in thermogenesis and could have an 
important role in energy expenditure. Brown adipocytes also display high glucose uptake 
and insulin sensitivity (195). However, the role of brown adipose tissue in the regulation of 
insulin sensitivity still needs further characterization.  
Glucose uptake in adipose tissue. As in skeletal muscle, insulin-stimulated glucose 
transport in adipose tissue is mediated by GLUT4. Although insulin resistance is 
characterized by defective glucose uptake in both muscle and fat, the amount of GLUT4 
decreases with increasing insulin resistance only in adipose tissue (196). Intracellular 
glucose is important for glycerol production in triglyceride synthesis. Glucose uptake, 
inhibition of lipolysis, and de novo synthesis of FFA are regulated by the PI3K pathway in 
adipocytes, whereas insulin’s effect on adipocyte proliferation is mediated via the Ras-
MAPK pathway (197). Adipocytes from subjects with T2DM are characterized by reduced 
IRS1 tyrosine phosphorylation (198), and altered adipose tissue insulin signaling through 
both the PI3K and Ras-MAPK pathways have been reported in insulin resistance and 
T2DM (108, 199, 200). Although adipose tissue accounts for only a small fraction of the 
whole body insulin-stimulated glucose disposal, adipocyte-specific ablation of GLUT4 in 
mice results in severe insulin resistance in liver and skeletal muscle (201), suggesting that 
adipose tissue regulates insulin sensitivity also in other target organs of insulin.  
Lipid metabolism in adipose tissue. Both impaired insulin mediated suppression of 
lipolysis and ineffective postprandial trapping of FFA in adipose tissue characterize insulin 
resistant states, giving rise to high postprandial circulating FFA levels (202). Lipid flux is 
diverted toward skeletal muscle and liver, followed by impaired insulin sensitivity in these 
organs (203-205). In accordance, obesity and T2DM are characterized by chronically 
increased FFA flux (206). Defects of adipose tissue lipid partitioning are further highlighted 
in subjects with total lipodystrophy, who are characterized by severe insulin resistance, 
hepatic steatosis, hypertriglyceridemia and defects in insulin secretion and finally by overt 
diabetes (207). Therefore, efficient trapping of FFA in adipose tissue is required to prevent 
from their harmful spill-over to non-adipose tissues.  
In the postprandial state, adipose tissue takes up fatty acids and glycerol from 
triglyceride rich lipoproteins and stores them as triglycerides. Lipoprotein lipase (LPL) 
hydrolyses the triglycerides and thereby controls fatty acid uptake in adipocytes. Insulin is 
a major regulator of LPL activity. Accordingly adipose tissue LPL is upregulated in the fed 
state and downregulated upon fasting (208). In subjects with T2DM reduced adipose tissue 
LPL activity has been reported (209), which could promote lipotoxicity.  
Adipocyte derived acylation stimulating protein (ASP) has been also recognized as a key 
regulator of fatty acid uptake and trapping. ASP enhances glucose uptake and triglyceride 
synthesis (210) and also inhibits lipolysis (211). Obesity is positively and insulin sensitivity 
negatively associated with ASP levels (212) suggesting that ASP may be involved in the 
regulation of insulin sensitivity.  
 In the fasting state triglycerides, stored in adipocytes, are hydrolyzed to glycerol and 
fatty acids (lipolysis) that are further transported to other tissues for energy production. 
Lipolysis is catalyzed by hormone-sensitive lipase (HSL) and monoacylglycerol lipase 
(MGL) (213). During fasting, insulin inhibits lipolysis via decreasing the activity of HSL by 
lowering intracellular cAMP level through phosphorylation and activation of cAMP 
specific PDE-3B (214). This effect is mediated by the PI3K pathway; more specifically Akt, 
which controls the activity of PDE-3B (215) (Figure 2.1). Insulin also decreases the FFA 
release by activating re-esterification of intracellular FFAs (211). 
Adipose tissue derived cytokines. Adiponectin. Adiponectin is a 30-kDa protein 
produced by adipocytes (216). Adiponectin levels are inversely correlated with body mass 
  
15 
index (217), reduced in obesity, and increased with weight loss (218). Accordingly, low 
adiponectin levels have been linked with insulin resistance, dyslipidemia and T2DM (218, 
219). In particular, adiponectin has been shown to regulate hepatic insulin sensitivity, and 
adiponectin levels correlate with both basal and insulin stimulated suppression of 
endogenous glucose production (220, 221). Adiponectin-treated animals increase glucose 
uptake and fatty acid oxidation in muscle and reduce hepatic glucose output (222, 223). 
Finally, adiponectin levels have been negatively associated with liver fat content and 
insulin resistance in T2DM (224). 
Leptin. Leptin is an adipose tissue-derived protein whose expression and circulating 
plasma concentration increases during the development of obesity (225). Obese subjects 
have been found to possess higher circulating levels of leptin than lean subjects (226), 
suggesting peripheral leptin resistance (146). Leptin acts both centrally and peripherally in 
controlling food intake, weight, energy balance and insulin sensitivity (227). In animal 
models chronic leptin treatment has improved insulin-stimulated glucose uptake by 
increasing GLUT 4 (228, 229). Insulin stimulates leptin expression (230), and obesity and 
insulin resistance are characterized by hyperleptinemia and hyperinsulinemia. 
Interestingly, leptin signaling interacts with insulin signaling, suggesting that leptin can 
also directly regulate insulin resistance (146, 231). Moreover, in mice leptin therapy corrects 
many of the negative metabolic consequences of insulin deficiency and suppresses 
hyperglucagonemia and hyperglycemia (232). 
Tumor necrosis factor α and interleukin-6. Low-grade inflammation with increased 
production of reactive oxygen species (ROS) characterizes obesity and drives insulin 
resistance (233). TNFα is a proinflammatory protein (234), which has been identified as an 
adipokine with a direct role in promoting insulin resistance and T2DM (235, 236), 
particularly in the context of obesity (237). TNFα expression is elevated in insulin resistant 
subjects in both skeletal muscle and adipose tissue (238, 239). TNFα attenuates IR signaling 
directly by decreasing its tyrosine kinase activity (240). TNFα also downregulates GLUT4 
and PPARγ expression in adipose tissue (241, 242).  
IL-6 is another proinflammatory protein produced by adipocytes (243) possibly 
promoting insulin resistance (244). IL-6 concentration predicts future T2DM (245) and 
weigh loss reduces IL-6 levels (246). IL-6 impairs insulin signaling by interfering with the 
IRS-1 activation and the PI3K pathway (247, 248). IL-6 also stimulates lipolysis and 
increases circulating FFA levels, which mediate its harmful effects on insulin sensitivity 
(249, 250).  
The roles of IL-6 and TNFα in the pathogenesis of insulin resistance remain to be 
elucidated, given a study suggesting that neither IL-6 nor TNFα are indicative of insulin 
resistance (251). 
Other adipokines. Animal studies revealed that serum resistin, a 12 kDa polypeptide, 
concentrations are elevated in mice models of obesity and diabetes, and that while 
antiresistin antibody administration improved glucose metabolism, resistin therapy seemed 
to impair insulin action (252). Moreover, resistin impairs skeletal muscle glucose uptake 
(144) and impairs AMPK signaling (145). However, human studies have yielded conflicting 
results (253-257). Thus the role of resistin in human insulin resistance remains largely 
unknown. 
A growing number of other adipokines with potential roles in insulin resistance have 
been described, including visfatin (258, 259), vaspin (260, 261), chemerin (262), omentin 
(263), and retinol binding protein-4 (RBP-4) (264). However, further studies are needed to 
clarify their physiological significance in humans (265). 
2.3.4 Insulin resistance in the liver 
Hepatic insulin resistance is a common feature of T2DM and insulin resistance syndrome, 
characterized by hepatic steatosis (266, 267). Defects in hepatic glucose uptake (268-271), 
  
16 
glycogen synthesis (272) and hepatic glucose production (128, 273) are all key components 
of hepatic insulin resistance. During fasting, hepatic glucose production and release are 
required to maintain adequate glucose delivery to vital organs for energy supply. Hepatic 
regulation of glucose homeostasis involves the uptake and storage of glucose 
(glycogenesis), formation and release of glucose both by gluconeogenesis and 
glycogenolysis, glucose degradation and oxidization (glycolysis and tricarboxylic acid 
cycle) and glucose usage as a substrate in pentose phosphate pathways in converting 
NADP (nicotinamide adenine dinucleotide phosphate) to NADPH (reduced NADP), an 
important reducing agent in lipid synthesis. Intracellular G6P can also be utilized in the 
production of various glycoproteins and peptidoglycans via the hexosamine biosynthesis 
pathway (274).  
In addition to direct glucose metabolism, glucose homeostasis is greatly influenced by 
hepatic lipid metabolism, including de novo lipogenesis, fatty acid oxidation and 
triglyceride synthesis and excretion. Insulin is a key regulator of both hepatic glucose and 
lipid metabolism. It suppresses hepatic glucose output, increases hepatic glucose uptake, 
activates both fatty acid and triglyceride synthesis and secretion, and suppresses fatty acid 
oxidation (81). Insulin signaling through IRS-1 seems to be important for insulin’s effect on 
glucose homeostasis, while IRS-2 mediated action is more involved in hepatic lipid 
metabolism (112).  
Hepatic glucose uptake and insulin resistance. Liver takes up glucose independently of 
insulin’s action through GLUT2. GLUT2 has a high capacity for glucose transport (275), 
which allows the rate of transport to be largely proportional to the ambient glucose 
concentration. Thus, high amounts of glucose can readily be taken up by the liver following 
a carbohydrate-containing meal. In fact, roughly one third of the glucose after an oral 
glucose load is taken up by the liver (276-278), while one-third is taken up by muscle and 
fat and one-third by non-insulin dependent tissues. Importantly, due to the marked insulin 
resistance in skeletal muscle the relative contribution of hepatic glucose uptake for 
postprandial glucose disposal is greater in people with T2DM (266). Hepatic glucose uptake 
is a determinant of hepatic glucose output and plays a central role in the pathogenesis of 
T2DM (279). Significant determinants of hepatic glucose uptake include glucose, insulin, 
glucagon, FFAs, and presumably the route of glucose entry (portal vs. peripheral) and 
neural regulation (266, 280). Also exercise increases hepatic glucose uptake (281).  
Hyperglycemia enhances hepatic glucose uptake independently of insulin and glucagon 
secretion. However, this glucose autoregulation is impaired in insulin deficiency and is 
ameliorated by insulin administration.  
Insulin increases hepatic glucose uptake both during euglycemia and especially during 
hyperglycemia (84, 269, 280). Insulin-mediated hepatic glucose uptake is defective in T2DM 
(269). Insulin regulates hepatic glucose uptake via direct and indirect (extrahepatic) effects 
which equally contribute to total hepatic glucose uptake (282). While in skeletal muscle the 
rate-limiting step in glucose uptake is transport through GLUT4, in the liver the rate-
limiting step is the phosphorylation of glucose,  controlled by hepatic glucokinase 
(hexokinase IV) (283, 284). Unlike other members of the hexokinase family, glucokinase is 
not under the negative feedback of G6P.  
In the basal state hepatic glucokinase is bound to a regulatory protein (GKRP) and is 
inactive (285), but when glucose level is elevated intracellularly, glucokinase and GKRP 
dissociate, and glucokinase becomes active, phosphorylating glucose into G6P. Mice 
overexpressing glucokinase demonstrate increased hepatic glucose uptake, glycolysis and 
glycogen synthesis (284, 286, 287). Defective action of glucokinase accompanies hepatic 
insulin resistance (288) and T2DM (289). Insulin is a positive regulator of hepatic 
glucokinase transcription (290). This action is mediated by the sterol regulatory element 
binding protein-1c (SREBP-1c) (291, 292), which is also a key regulator of hepatic lipid 
metabolism.  
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In addition to the direct effect of insulin on hepatic glucose uptake, insulin inhibits 
lipolysis in adipose tissue, thereby reducing the FFA flux into the liver. Elevated levels of 
FFAs impair insulin-mediated hepatic glucose uptake (293) and cause hepatic insulin 
resistance at multiple sites (294). 
Hepatic glucose production and insulin resistance. The liver is the primary glucose-
producing organ, providing 90% of the glucose during fasting (79). The exact contribution 
of kidneys to the endogenous glucose production has remained unclear, but could be 
underestimated (295). Gluconeogenesis and glycogenolysis affect the total hepatic glucose 
release rate approximately equally, although prolonged fasting significantly reduces 
hepatic glycogen stores and thus the proportion of glycogenolysis (266). In the post-
absorptive state the healthy liver produces glucose at the rate of 2 mg/kg/min (76). In T2DM 
the increased basal hepatic glucose production rate is strongly correlated with the level of 
hyperglycemia. Although hyperglycemia is accompanied by hyperinsulinemia, which 
normally efficiently inhibits hepatic glucose output, insufficient suppression of hepatic 
glucose production (HGP) by insulin is the most important feature of hepatic insulin 
resistance in T2DM (296). Both amplified gluconeogenesis and glycogenolysis play a role in 
the elevated HGP in T2DM (297).  
Glucagon and insulin are major regulators of glucose production. When glucose levels 
fall, pancreatic α-cells release glucagon, which induces gluconeogenesis, prompts glycogen 
breakdown, and promotes adipose tissue lipolysis. De novo glucose synthesis in the liver 
requires the utilization of gluconeogenic precursors such as lactate, amino acids and 
glycerol. Phosphoenolpuryvate carboxykinase (PEPCK) catalyzes the rate limiting step of 
gluconeogenesis whereby oxaloacetate is transformed to phosphoenolpuryvate. Glucose-6-
phosphatase in turn catalyzes the final step of gluconeogenesis and glycogenolysis by 
hydrolyzing G6P into glucose. Insulin suppresses HGP through PI3K/Akt dependent 
phosphorylation of FOXO1, a transcription factor which in concert with the PGC-1α 
regulates transcription of key enzymes of gluconeogenesis, PEPCK and glucose-6-
phosphatase (298). PEPCK and glucose-6-phosphatase can also be downregulated through 
AMPK as in the case of the insulin sensitizers adiponectin (see section 2.3.3) and metformin, 
an anti-diabetic drug, which both suppress gluconeogenesis (299-301). 
Insulin is known to alter the expression of several other transcriptional regulators in the 
liver, including hepatic nuclear factor-3 (HNF-3), FOXO3, and liver X receptors (LXRs) and 
co-activator proteins like PGC-1 that might also contribute to insulin’s inhibitory action on 
HGP (302). Insulin also inhibits glycogenolysis by stimulating Akt dependent inhibition of 
glycogen phosphorylase activity (303). These mechanisms suppressing gluconeogenesis are 
compromised in insulin resistant states. Insulin’s key role in the control of hepatic glucose 
production is highlighted by the LIRKO mice, which are characterized by non-inhibited 
hepatic glucose production due to elevated PEPCK and glucose-6-phosphatase expression 
(127). Findings in these mice have also confirmed that intact insulin receptor signaling is 
required for both direct and indirect effects of insulin in the liver (128). The physiological 
significance of PEPCK and glucose-6-phosphatase is emphasized by studies showing that 
overexpression of these enzymes results in glucose intolerance in rodents (304, 305).  
In summary, disproportional glucose production in T2DM results from dysfunctional 
cross-talk of several organs and includes hepatic insulin resistance, relative pancreatic 
hypersecretion of glucagon, and increased availability of gluconeogenetic precursors from 
peripheral depots (FFA and glycerol) (205, 279). Moreover, peripheral insulin resistance can 
augment hepatic glucose output, as impaired insulin suppression of lipolysis elevates 
circulating FFA thus contributing to increased hepatic gluconeogenesis. 
Hepatic glucose storage and breakdown. Skeletal muscle and liver are the main sites for 
glucose storage in the form of glycogen. After a meal approximately 20% of carbohydrates 
are stored in the liver as glycogen (306, 307). Hepatic glycogen metabolism is regulated by 
two key enzymes – GS and glycogen phosphorylase (GP). Hepatic glycogenesis and 
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glycogenolysis can occur simultaneously resulting in glycogen cycling. Hyperglycemia 
decreases glycogenolysis by reducing the activity of GP, whereas insulin activates glycogen 
synthesis by activating PP-1. PP-1 increases the activity of GS by direct activation and by 
removing the inhibitory effect of GSK-3 through phosphorylation (106). Insulin mediates its 
effect on glycogen synthesis via the PI3K pathway (Figure 2.1). Simultaneously, Akt 
reduces the activity of GP thereby inhibiting glycogen breakdown (308). Importantly, in 
individuals with T2DM reduced hepatic glycogen stores and glycogen synthesis rate after a 
mixed meal and during clamp have been reported (272).  Similarly, net glycogenolysis 
during the postabsorptive period is reduced in subjects with T2DM, with an increased 
contribution of gluconeogenesis to glucose production (272, 309). Moreover, when hepatic 
glycogen stores are full, glucose is diverted to glycolysis, providing carbons for lipid 
synthesis promoting hepatic lipid accumulation and insulin resistance. 
Hepatic lipid metabolism and insulin resistance. The liver participates in several 
processes involved in lipid metabolism including fatty acid oxidation, de novo lipogenesis, 
cholesterol and bile acid synthesis and lipoprotein assembly and lipid secretion. 
Hepatic fat accumulation, i.e. steatosis, is closely correlating with hepatic insulin 
resistance in subjects with and without T2DM (267, 310-312). De novo lipogenesis is known 
to be disproportional in subjects with obesity and fatty liver (313) and in lean, insulin 
resistant offspring of subjects with T2DM (314). In mice, a high fat diet has been shown to 
induce hepatic insulin resistance, which can be ameliorated by inhibiting hepatic lipid 
accumulation (315). On the other hand, insulin’s lipogenic potential in the liver does not 
seem to become compromised in chronic insulin resistant states, which are characterized by 
hypertriglyceridemia and by both hepatic and peripheral fat accumulation (316). This is 
consistent with LIRKO mice, which manifest hyperglycemia and hyperinsulinemia, but also 
low levels of liver and circulating triglycerides (317). Similar results have been obtained in 
humans with IR mutations or antibodies toward IR (318). Insulin induces lipid synthesis in 
the liver by activating SREBP-1 which enhances the transcription of several genes involved 
in lipid metabolism including Acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS) 
(319,320). In addition, both insulin and glucose can induce lipogenesis through 
carbohydrate response element binding protein (ChREBP) (321).  
SREBP-1 acts in concert with the nuclear receptor liver X receptors (LXRs) (322). LXRs 
are vital regulators of cholesterol metabolism, but also involved in hepatic lipogenesis and 
glucose metabolism (323). Importantly, LXRs target adipocyte differentiation via PPARγ 
(324). Activation of both PPARγ1 and -γ2 promote hepatic lipid accumulation (325, 326). 
On the other hand, AMPK activation inhibits SREBP-1 (301). 
The insulin signaling mechanisms driving SREBP-1 transcription are currently unclear, 
but could be related to aPKC activation (327). Synthesized lipids are excreted as 
triglycerides within very low-density lipoproteins (VLDL) for peripheral transport and 
storage. As insulin resistant states are accompanied by hyperinsulinemia, 
hypertriglyceridemia ensues, providing fuel for lipotoxicity and worsening insulin 
resistance in the liver and peripheral tissues (328). 
Another mechanism through which insulin can promote lipotoxicity is by suppressing 
FFA oxidation in the liver. This is partly because the activation of ACC inhibits CPT-1 and 
subsequently reduces FFA transport into mitochondria for oxidation (329). Hepatic lipid 
accumulation is also accompanied by increased transcription of inflammatory pathways 
(330), suggesting that similar low grade inflammation that is evident in adipose tissue 
could exist with hepatic steatosis promoting its progression to non-alcoholic steatohepatitis 
and cirrhosis (331).  
In summary, hepatic lipid metabolism is an important player in hepatic and systemic 
insulin resistance. Insulin resistance can lead to fatty liver, whereas hepatic fat 
accumulation can lead to hepatic insulin resistance (316).  
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2.4 THE HEXOSAMINE BIOSYNTHESIS PATHWAY AND INSULIN 
RESISTANCE 
Approximately 3% of glucose utilization is routed via the hexosamine biosynthesis 
pathway (HBP) (332). This pathway is known to interact with insulin signaling pathways 
(333). The rate-limiting enzyme converting fructose-6-phosphate to glucosamine-6-
phosphate is fructose-6-phosphate amidotransferase (GFAT). Overexpression of GFAT in 
mouse skeletal muscle led to hyperinsulinemia and insulin resistance (334), while 
overexpression of GFAT in the liver drives glycogen storage, suggesting that HBP acts as 
fuel sensor mediating the fed state signal (335). Mice overexpressing GFAT in the liver were 
hypoglycemic and –insulinemic but developed obesity and insulin resistance over time. 
These changes are accompanied by hypertriglyceridemia and high circulating FFA. Thus, 
active HBP would sense calorie excess and direct the metabolism towards fat storage (336). 
Moreover, a potent inhibitor of GFAT prevents insulin resistance in adipocytes and 
subsequent treatment with glucosamine (substrate for HBP) restores this insulin resistant 
phenotype (332, 336, 337). 
In humans, GFAT activity has been shown to be increased in subjects with T2DM in 
skeletal muscle (338). Studies have indicated that flux through HBP leads to increased 
oxidative and endoplasmic reticulum (ER) stress (see section 2.5), that have been shown to 
cause insulin resistance (339). Despite the substantive evidence linking flux through the 
HBP with insulin resistance, further studies are needed to clarify the role of HBP in the 
pathogenesis of insulin resistance and T2DM (333, 339, 340). 
2.5 INFLAMMATION, ENDOPLASMIC RETICULUM STRESS AND INSULIN 
RESISTANCE 
Obesity, T2DM and other insulin resistant states are associated with markers of 
inflammation, including plasminogen activator inhibitor-1, fibrinogen, TNFα, IL-6, IL-8 and 
C reactive protein (CRP) (239, 341-345). Also, cellular targets of these cytokines include c-
Jun-N-terminal kinase (JNK) which is known to interact with insulin signaling through 
IRS1 phosphorylation (see section 2.2) and nuclear factor-κB (NF-κB) which directly 
influences transcription of inflammatory mediators (240, 346-349). NF-κB activates 
transcription of inflammatory proteins that in turn are able to activate both JNK and NF-κB 
pathways (349). Insulin resistant states are associated with chronic activation of these 
proinflammatory pathways (330, 346). In contrast, insulin sensitivity is associated with 
deactivation of these pathways (350-353). 
FFA derivatives can activate inflammatory pathways, and pharmacological inhibition of 
these pathways prevents obesity induced insulin resistance (354). Adipose tissue is known 
to secrete several cytokines (see section 2.3.3) including TNFα and ILs that take part in 
inflammatory signaling. Although the processes initiating inflammation in adipose tissue 
are unknown, adipocyte hypertrophy, under energy surplus, hypoxia and cellular 
oxidative stress (including ROS) are likely to be involved (355). In particular, ER stress has 
been shown to be increased in obesity. ER stress activates JNK and NF-κB and 
downregulates insulin signaling (349, 356). 
Activation of inflammatory pathways stimulates cytokine and chemokine release and 
recruits macrophages into adipose tissue, escalating the inflammation even more (355). 
Macrophages take part in cytokine release and induce insulin resistance via paracrine 
effects (354). The role of macrophages is emphasized in mice models of myeloid knock-out 
of JNK and NF-κB pathways, and TNFα. These mouse models are protected from obesity 
induced insulin resistance (357-359).  
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Visceral adipose tissue seems to be more susceptible to inflammation than subcutaneous 
adipose tissue (360). In addition to altered cytokine secretion from adipocytes and 
macrophages, inflammation enhances lipolysis and thereby increases fatty acid flux to 
skeletal muscle and liver influencing systemic insulin sensitivity (361). Saturated fatty acids 
have also been proposed to activate inflammatory pathways and subsequently reduce 
insulin sensitivity (362). On the other hand, lifestyle intervention in insulin resistant 
subjects has shown to reduce the level of inflammatory markers (363, 364). Furthermore, 
antidiabetic drugs including thiazolidinediones and metformin also reduce inflammation 
(363, 365). Inflammation is a common feature of insulin resistance, atherosclerosis, obesity 
and hypertension, and adipose tissue dysfunction and inflammation have been proposed to 
link these conditions (366, 367). 
2.6 NUCLEAR RECEPTORS 
2.6.1 The nuclear receptor superfamily 
The process of transferring genomic information from deoxyribonucleic acid (DNA) to 
ribonucleic acid (RNA) is called gene transcription. This process is regulated by numerous 
transcription factors, i.e. proteins that bind to DNA at specific binding sites close to the 
transcription initiation complex and commence or modulate the rate of gene transcription. 
Nuclear receptors are one of the most abundant classes of transcriptional regulators, vital in 
the embryonic development, maintenance of differentiated cellular phenotypes, 
metabolism, and cellular death (368). In humans, the nuclear receptor superfamily 
comprises of 48 individual nuclear receptors categorized by their sequence homology (369) 
including glucocorticoid, mineralocorticoid, sex hormone, retinoic acid, thyroid hormone, 
vitamin D, and PPARs. The nuclear receptor superfamily is divided into seven subfamilies 
(NR0-6) (further divided into a number of groups) according to phylogenetic resemblance 
of the individual receptors (370). 
2.6.2 Structure of the nuclear receptors 
Nuclear receptors that belong to subfamilies NR1-6 share a common structure with five 
functional regions or domains (Figure 2.2). The variably sized (from less than 50 to over 500 
amino acids) amino (N-) terminus contains a transactivation domain (A/B domain) 
harboring at least one constitutionally active transactivation region (AF-1) and several 
autonomous transactivation domains (AD) able to interact with various cofactors (371). The 
central, conserved DNA binding domain (DBD) holds from 66 to 68 amino acids and has 
two zinc-finger motifs common for the entire superfamily of nuclear receptors. DBD 
includes the P-box, a small motif capable of recognizing specific DNA binding site i.e. 
response element (371). The carboxy(C-) terminal ligand-binding domain (LBD) varies in 
length from 200 to 250 amino acids containing the transactivation function (AF-2) that is 
able to interact with transcriptional co-activators in a ligand-dependent manner (368). In 
addition, the nuclear receptors hold a less conserved region called D domain or hinge 
between the DBD and LBD. This domain contains the nuclear localization signal (NLS) 
tagging the receptor for nuclear import.  Also, nuclear receptors may contain a final 
carboxy-terminal region, the F domain, whose functions are poorly characterized (371). 
However, recent studies suggest that this domain has important modulatory actions (372, 
373). Among these domains, the DBD and LBD share highest similarity in most nuclear 
receptors (374). The unusual nuclear receptors belonging to the NR0 subfamily contain 
similar transactivation domain, but are lacking either DBD or LBD.  
In addition, many nuclear receptors are expressed as several isotypes, for instance 
estrogen receptor α and –β, and PPARα, -β/δ, and –μ). Commonly, different isotypes vary 
by their expression sites and function, contributing to signal diversification and 
specification (368). 
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Figure 2.2 The common structure of nuclear receptors (371). The N-terminal A/B domain 
contains the AF-1 function, the C domain (DBD) is responsible for DNA binding, the D domain 
contains the nuclear localization signal (NLS), the largest E domain (LBD) harbors AF-2 activity 
and ligand-dependent NLS, and is responsible for ligand binding, and some but not all nuclear 
receptors also contain the F domain at the C-terminal end, whose functions are poorly 
understood. 
2.6.3 Mode of action of the nuclear receptors 
Nuclear receptors can act as monomers, homodimers, or heterodimers with retinoid X 
receptor (RXR). They are considered to be ligand-activated, but the specific ligands for a 
number of nuclear receptors are yet to be found or do not exist (so called orphan receptors). 
Classically, nuclear receptors are classified as type 1 or type 2 receptors (375). Upon binding 
of the receptor with its ligand in the cytoplasm, the type 1 receptor undergoes a 
conformational change, after which it is translocated into the cell nucleus, where it binds to 
DNA. In contrast, type 2 receptors are retained in the nucleus regardless of the presence of 
the ligand. 
The DNA binding occurs at specific hormone response elements (HRE) within the 
regulatory regions of the target genes. HREs are formed by a repetition of the core 
consensus motif PGGTCA, where P refers to a purine. Nuclear receptors that 
heterodimerize with RXR bind to direct repeats of the core motif (e.g. 
AGGTCA_AGGTCA). The spacing between the two halves of the direct repeat determines 
the type of the nuclear receptor able to bind to the particular response element. The binding 
specificity of monomeric nuclear receptors is determined by the A/T rich sequence 5’ to the 
core motif. Only orphan receptors are known to bind to HREs as monomers (376). 
Classically, nuclear receptors are thought to act in three ways: repression, derepression 
and transcription activation (371). In the absence of a ligand, nuclear receptors interact with 
co-repressor proteins (Figure 2.3). Repression is mediated via a co-repressor complex 
having histone deacetylase (HDAC) activity and leads to a condensed packing of chromatin 
locally. Derepression takes place after ligand binding, resulting in dissociation of the co-
repressor complex and recruitment of a co-activator complex with histone acetyltransferase 
(HAT) activity. Thereafter chromatin decondenses and HAT complex dissociates allowing 
the recruitment of a new co-activator complex and subsequent transcriptional activation. 
However, some nuclear receptors can activate transcription of target genes without a ligand 
and others can not bind to DNA (and trigger repression) in the absence of a ligand. In 
addition, some nuclear receptors can alter gene expression by cross-talk with other 
transcription factors without binding to DNA through a mechanism termed receptor-
dependent trans-repression (377) Also, post-translational modification (e.g. 
phosphorylation, acetylation, SUMOylation, ubiquitylation and methylation) and cyclic 
degradation of the nuclear receptors and co-regulators through the ubiquitin-proteasome 
pathway modulate the transcriptional process (378-380). Moreover, the cellular amounts of 
nuclear receptors are regulated mainly by the availability of associated ligands (379). 
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Figure 2.3 Schematic representation of a heterodimerized (e.g. PPAR/RXR) nuclear receptor 
action (371). A. In the absence of a ligand, nuclear receptor (NR) is bound to a co-repressor 
(CoR) and associated complex which binds proteins with histone deacetylase activity (HDAC). 
Chromatin is condensed and target gene transcription repressed. 
B. After ligand binding (L1, L2), CoR is released and co-activator (CoA) and associated complex 
is recruited with histone acetyl transferase (HAT) activity allowing chromatin decondensation 
and activation of target gene transcription. LBD, ligand binding domain; DBD, DNA binding 
domain. 
2.6.4 Nuclear receptor ligands 
Ligands for nuclear receptors can be endocrine, paracrine, autocrine, or intracrine in nature. 
Commonly, these ligands are lipophilic, granting an advantage of free passage through the 
lipid bilayer of cellular membranes (381). The LBD of the nuclear receptors can bind 
numerous small molecules including the natural ligands of the receptor, synthetic agonists 
and antagonists, and molecules resembling natural ligands (382). The LBD consists of a 
helical mesh that forms a pocket where ligands are bound. The receptors with a large 
ligand binding pockets like PPARs can bind a large variety of ligands with relatively weak 
affinity whereas receptors that bind with high affinity to a specific ligand have small ligand 
binding pockets (374, 376, 382). Ligands play important roles in determining the cofactors 
recruited, and nuclear receptor functions are closely coupled with their cognate ligands 
(374). 
2.6.5 Nuclear receptor co-regulators 
Nuclear receptor activity is regulated by the binding of specific ligands, and the regulatory 
effect is mediated by a variety of co-regulators that are defined as co-repressors and co-
activators on the basis of their requirement for transcription repression or activation (383). 
These co-regulators are not specific for nuclear receptors, but can regulate also the function 
of other transcription factors (378). Although most unliganded nuclear receptors interact 
with co-repressors, and recruit co-activators upon ligand binding, some co-repressors are 
able to bind nuclear receptors in a ligand-dependent manner competing with co-activators 
(384). Co-regulators can associate with a large variety of multiprotein co-regulator 
complexes and have different action in different settings (385). Their modes of action 
include covalent modification of histones (for instance by acetylation, deacetylation, 
methylation, demethylation, phosphorylation, dephosphorylation, ubiquitylation, 
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deubiquitylation), modulation of promoter accessibility to transcription factors and 
transcriptional machinery, and assembly, recruitment and release of co-regulator 
complexes (378). Co-regulators seem to be recruited in a coordinated and precisely timed 
fashion, but the mechanisms controlling these events are yet largely unknown (378). 
2.7 THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPARS) 
2.7.1 PPARα 
Structure, expression, ligands and target genes of PPARα. In 1990 an orphan member of 
the steroid hormone receptor superfamily was shown to be activated by peroxisome 
proliferators (386), hence this subfamily was later-on known as PPARs. PPARα was the first 
human PPAR cloned (387). PPARα harbors a functional domain similar to those of all other 
nuclear receptors including DNA binding domain, ligand binding domain and activating 
function  domains 1 and 2 (AF-1, AF-2) (see section 2.6.2). The activation of the PPARα 
includes heterodimerization with retinoid X receptor (RXR) and possible co-activation or 
co-repression with other molecular targets and subsequent changes in gene transcription. A 
number of hormones, e.g. insulin, activate PPARα through MAPK dependent 
phosphorylation (388, 389). PPARα is primarily expressed in tissues with a high activity for 
fatty acid oxidation such as liver, skeletal muscle, heart, kidney, and brown fat (390,391).  
Several synthetic compounds have been shown to activate PPARα. These include 
commonly used non-steroidal anti-inflammatory drugs (392) and fibrates, which are used 
to treat cardiovascular disease and dyslipidemia (hypertrigyceridemia in particular) in 
humans (393, 394). Fatty acids and eicosanoids and leukotrienes are natural ligands for 
PPARα (393, 395). It has been proposed that FFAs from different sources (diet, de novo 
synthesis, or lipolysis) have distinct abilities to activate PPARα (396). Very recently, a 
phospholipid (1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16/18-GPC)) has been 
identified as an endogenous ligand for PPARα (397). Finally, glucocorticoids are among the 
known PPARα agonists (398, 399), and glucose has been shown to downregulate PPARα in 
the pancreas, possibly inducing lipotoxicity (400).  
Activation of PPARα, in turn, drives the expression of key proteins of fatty acid uptake, 
mitochondrial transport of fatty acids, fatty acid oxidation, lipogenesis, cholesterol 
metabolism,  ketogenesis, and gluconeogenesis including fatty acid transport protein-1 
(FATP-1), hepatic FABP-4 (aP2), acyl-CoA binding protein (ACBP), CD36, CPT-1 and -2, 
mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase (mHMGCoAS), and LPL (391, 
401). In contrast to the enhancement of pathways of lipid oxidation, activation of PPARα 
represses gene expression of inflammatory pathways including IL-6, cyclo-oxygenase-2 and 
NF-κB (402). Both altered lipid metabolism in particular in terms of lipotoxicity and low-
grade inflammation are associated with insulin resistance and T2DM (403) implying that 
PPARα could participate in the pathogenesis of theses states.  
PPARα and insulin sensitivity. Several lines of evidence suggest that PPARα may have 
a role in the regulation of glucose homeostasis and insulin sensitivity, particularly in the 
liver. However, most data are from animal studies and should be interpreted with caution 
since there are species-specific differences in PPARα action (404, 405). Loss of PPARα 
function in mice leads to aggressive hepatic lipid accumulation and steatosis due to 
ineffective lipid oxidation under conditions of high hepatic FFA delivery as during fasting 
or high fat diet (406). In addition to elevated circulating FFAs, fasting PPARα null mice are 
also characterized by marked hypoglycemia, relative hyperinsulinemia, hypoketonemia, 
and hypothermia (406, 407). Marked hypoglycemia may be due to impairments in hepatic 
glycerol metabolism, gluconeogenesis, and glycolysis (408, 409) and inefficient suppression 
of insulin secretion (410). 
PPARα can also directly regulate hepatic insulin signaling pathway through TRB-3 
protein which inhibits insulin signaling by preventing activation of Akt (see section 2.2) 
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(411, 412). In addition, glucocorticoids induce insulin resistance, which is mediated by 
PPARα (413). In concert, PPARα -/- mice are protected from high-fat -diet induced systemic 
insulin resistance despite increased adiposity (414). However, in animal models, treatment 
with PPARα agonists has been shown to improve insulin sensitivity, possibly by improved 
fatty acid handling and reduced lipotoxicity (391, 405). Human studies with fibrates 
(PPARα agonists) have yielded inconsistent results with some showing an increase in (415-
417) and others no effect on insulin sensitivity (418, 419). In contrast, fibrates reduce plasma 
triglycerides and LDL cholesterol and increase HDL cholesterol levels in humans (420).  
Interestingly, mice studies show that in skeletal muscle PPARα activation reduces 
glucose uptake by decreasing GLUT4 expression, possibly due to the diversion of the 
energy metabolism towards lipid utilization (421). The role of PPARα in skeletal muscle 
fuel control is also affected by a possible compensatory role of PPARδ in skeletal muscle 
fatty acid metabolism (422). These data highlight the unique organ-specific actions and 
interactions of PPARα on glucose and lipid metabolism. Furthermore, PPARα regulates 
adipokine secretion and thereby could indirectly influence insulin sensitivity (423). 
Although the role of PPARα in the control of insulin sensitivity is unclear, a number of 
studies indicate that PPARα is clearly involved in the regulation of insulin secretion (424-
428). On the other hand, the regulation of insulin secretion by PPARα may be dependent on 
the underlying insulin resistance, since PPARα null mice exhibit similar glucose-stimulated 
insulin secretion as wild type mice (414), while obese insulin resistant mice with PPARα 
deficiency are characterized by beta cell dysfunction (427). 
PPARα gene polymorphisms. PPARα gene (PPARA) is located on chromosome 22q12-
q13.1 (387) and contains 8 exons (429). Variants of PPARA have been associated with lipid 
levels, body mass index, signs of visceral obesity, non-alcoholic fatty liver disease, physical 
performance, age of onset and progression to T2DM, cardiovascular disease, but not with 
insulin sensitivity as of to date. Most studied polymorphisms of the PPARA include two 
missense SNPs causing an amino acid change in the PPARα protein, Leu162Val (429) and 
Val227Ala (430) polymorphisms.  
The Leu162Val polymorphism affects the DBD of PPARα with the Val162 allele showing 
greater transactivation potential upon ligand activation (431). The allelic frequency of 
Val162 is approximately 6-7% in Europeans, 3% in Asians and 1-2% in African Americans 
(431-435). The minor Val allele has been associated with higher total, LDL and HDL 
cholesterol, triglyceride and apolipoprotein concentrations in subjects with T2DM (429, 431, 
432, 434, 436-438). Some studies have reported that the Val162 allele is linked with obesity 
(433, 439), but other studies have failed to replicate these findings (432). Also fibrate 
treatment in subjects with the Val162 allele results in greater reduction of total and non-
HDL cholesterol and greater elevation of HDL cholesterol (431, 440, 441). The Leu162Val 
polymorphism has been shown to modulate the risk of cardiovascular events in insulin 
resistant subjects, possibly by modifying atherogenic lipid profile and mediators of 
inflammation (442-444). Although cross-sectional studies have not found any association of 
the Leu162Val polymorphism with T2DM (429, 431, 433), a follow-up study suggested a 
1.9-fold risk for conversion of impaired glucose tolerance to T2DM in carriers of the G 
(Val162) allele (445), and a combination of the Leu162Val polymorphism with other SNPs of 
PPARA have been shown to influence the age of onset and progression of T2DM (446). 
A T→C change resulting in the Val227Ala polymorphism located between the DNA 
binding and ligand binding domain of PPARα protein has been reported (430). This PPARα 
site is thought to be important for the obligatory heterodimerization, which could be 
thereby influenced by this polymorphism. However, experiments confirming a functional 
difference between the two alleles have not yet been performed. The minor Ala allele 
frequency has been reported to be around 4-5% in Asians (447, 448). The Val227Ala 
polymorphism has been reported to be associated with serum lipid levels with carriers of 
the Ala227 allele showing lower total cholesterol and triglyceride levels than subjects with 
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the Val227Val genotype, particularly in women (447, 448). Recently, this polymorphism has 
been associated with lower body mass index (BMI) and a reduced risk of non-alcoholic 
fatty liver disease (449). 
2.7.2 PPARδ 
Structure, ligands, target genes and function of PPARδ. The second human member of the 
PPAR family, PPARδ (also PPARβ, NUC1, NR1C2) consists of the same components, 
including ligand binding, DNA binding, and AF-1 and -2 domains, as other PPARs (Figure 
2.2). The ligand-binding pocket of the PPARδ protein has been shown to be fairly large, 
comparable to that of PPARγ, allowing the binding of unsaturated and saturated fatty acids 
and synthetic substances e.g. fibrates (450). In addition to synthetic ligands, fatty acids, 
especially from VLDL (451) and eicosanoids can act as PPARδ activators (393). In addition 
to ligands, co-activators and co-repressors can modulate the ligand-induced PPARδ 
activation (452). Compared to PPARα and –γ, PPARδ has more ubiquitous expression with 
high expression levels in the heart, skeletal muscle, central nervous system, adrenal, skin 
and intestine, but also white and brown adipose tissue and liver (453-456). Importantly, the 
expression levels of PPARδ in skeletal muscle are several-fold compared with those of 
PPARα and –γ (456, 457), suggesting that it is the dominant metabolism regulating isoform 
of PPARs in this tissue.  
Direct and indirect PPARδ target genes include genes responsible for fatty acid uptake, 
transport, storage and oxidation (e.g. CPT-1, HSL, FABP-3, FAT/CD36, LPL, aP2) (451, 458-
461), thermogenesis, energy dissipation and mitochondrial function (Uncoupling protein 
(UCP)-1, -2, PGC-1α) (459, 462), and inflammation (monocyte chemoattractant protein-1 
(MCP-1), IL-1β) (453,463). Induction of several PPARδ target genes can be further enhanced 
by combining PPARδ agonist with a RXR agonist (460).  
Generation of PPARδ-/- mice showed that PPARδ has a role in placental (464) and 
adipose tissue development (adipocyte differentiation and proliferation), myelinisation, 
inflammation and wound healing (keratinocyte development) (454, 465-469). Interestingly, 
PPARδ seems to coordinately regulate the adipocyte development with PPARγ so that 
although PPARδ expression is not obligatory for adipocyte differentiation driven by 
PPARγ, the maximal PPARγ dependent differentiation potential is achieved only in co-
operation with PPARδ (461). In addition, PPARδ has been shown to be involved in the 
regulation of lipid and glucose metabolism, insulin sensitivity, inflammatory signaling, 
cholesterol metabolism and atherosclerosis, cardiac and skeletal muscle oxidative 
metabolism, and possibly carcinogenesis (454, 470-473). 
PPARδ and insulin sensitivity. PPARδ knock-out mice display decreased metabolic rate 
and lower food consumption as compared with wild type littermates (453). They also 
display delayed normalization of blood glucose after a glucose load as an indication of 
reduced glucose tolerance. In addition, a PPARδ agonist treatment improved glucose 
tolerance in wild type, but not in PPARδ knockout mice. Accordingly, PPARδ agonist 
treatment improved peripheral and especially hepatic insulin sensitivity in diabetic (db/db) 
mice (453). Gene-expression studies in these mice indicated that PPARδ agonist treatment 
induced genes involved in lipid synthesis and pentose phosphate pathway in liver while 
activating lipid oxidation in skeletal muscle. Thus fatty acid synthesis in liver provides fuel 
for skeletal muscle β-oxidation. Accordingly, PPARδ activates adipose tissue lipolysis. The 
role of PPARδ in lipid oxidation and prevention from lipotoxicity is also evident in cardiac 
muscle-specific PPARδ knock-out mice, which develop progressive myocardial lipid 
accumulation and cardiac hypertrophy and heart failure as a consequence of reduced 
myocardial fatty acid oxidation (474). 
Mice expressing constitutively active form of PPARδ in brown and white adipose tissue 
have reduced body weight and adiposity and decreased level of circulating FFA compared 
to normal mice (459). These alterations are mostly due to activated lipid oxidation in brown 
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fat. Likewise, PPARδ knockout mice have a tendency toward weight gain during high fat 
feeding owing to reduced energy dissipation, while mice with constitutively active PPARδ 
in adipose tissue are resistant to diet-induced obesity (459). Therefore, PPARδ activation 
could prevent from obesity-associated insulin resistance. This is also supported by research 
demonstrating that PPARδ agonist treatment ameliorated diet induced insulin resistance in 
high fat fed and genetically obese mice (462). Again, this was accompanied by enhanced 
muscle fatty acid utilization, energy dissipation and subsequent reduction in skeletal 
muscle and hepatic lipid content. Despite the reduction in glucose usage caused by the 
increased utilization of fatty acids, net result of PPARδ activation is improved insulin 
sensitivity (475). However, some PPARδ agonists can also directly enhance insulin-
independent glucose uptake in skeletal muscle by stimulating the AMPK-dependent 
pathway (see section 2.3.2) independently of PPARδ (476, 477). 
Constitutive PPARδ activation in skeletal muscle in mice results in an increase in slow 
oxidative type 1 fibers (fiber type switch) and number of mitochondria (458). Consequently, 
these mice are lean and have increased exercise endurance and improved metabolic profile. 
However, fiber type switch is not seen in a mouse model of skeletal muscle PPARδ 
overexpression (478), demonstrating a possible limiting role of endogenous receptor 
ligands (454). Both physical activity and fasting have been shown to increase muscle 
PPARδ expression in mice and humans providing further evidence for PPARδ’s possible 
role as a major regulator of skeletal muscle oxidative capacity (478-481).  
Although the role of human brown fat in whole body metabolism may be minor, skeletal 
muscle and liver are major determinants of total insulin sensitivity suggesting that PPARδ 
could be involved in the regulation of insulin sensitivity in humans. Recently, in a small 
pilot study a PPARδ agonist treatment was shown to improve dyslipidemia, decrease 
circulating FFA levels, reduce hepatic steatosis and improve insulin sensitivity in 
moderately obese men (482). In addition, PPARδ activation may control adipokine 
secretion, providing yet another mechanism for PPARδ-dependent regulation of insulin 
sensitivity (423, 483, 484). 
PPARδ gene polymorphisms. PPARδ gene (PPARD) is located on chromosome 6p21 
and several SNPs in the PPARD have been described (485, 486). A +294 T->C (rs2016520) 
polymorphism in exon 4 of PPARD has been associated with cholesterol levels (487-490) 
and fasting plasma glucose (486). This polymorphism influences the binding of a 
transcription factor Sp-1 with the rare C allele associated with higher transcriptional 
activity (487). Very recently this polymorphism was shown to associate with reduced 
height (491), which is a known risk factor for T2DM and impaired glucose tolerance (492). 
Other PPARD polymorphisms have shown inconsistent associations with fasting glucose 
concentrations, BMI and insulin sensitivity (486, 493). SNPs in PPARD have been associated 
with an increased risk of developing diabetes in a prospective study in subjects with 
impaired glucose tolerance (494). In addition, genetic variants of PPARD associated with 
changes in physical fitness and insulin sensitivity during diet and exercise intervention 
(495) and adiposity and body composition (496). However, a large population based cross-
sectional study failed to show any association of several SNPs with HOMA-IR, serum lipids 
or measures of adiposity including BMI (485) and genome wide association studies did not 
confirm the association of PPARD polymorphisms and T2DM. 
2.7.3 PPARγ 
Of all the PPARs, the third family member PPARγ is by far the most studied. It has been 
shown to participate in numerous processes controlling energy balance, glucose and lipid 
metabolism and insulin resistance (497, 498). Modulation of PPARγ activity in different 
tissues produces different phenotypic characteristics. Variations in the human PPARG can 
affect the risk of insulin resistance and T2DM. 
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PPARγ gene, proteins, and ligands. In humans, the PPARγ gene (PPARG) is located on 
chromosome 3 at 3p25 and spans over 100kb of DNA (499). By alternative promoter usage, 
PPARG can translate into four different mRNA subtypes (PPARγ mRNAγ1-4) (500-502). 
However, of these mRNAγ1,3,4 translate into the same protein PPARγ1 whereas mRNAγ2 
encodes a different protein, PPARγ2 (Figure 2.4). PPARγ2 protein harbors an additional 28 
amino acids compared to PPARγ1 encoded by the exon B of mRNAγ2. Both isoforms are 
found predominantly in adipose tissue (503, 504). The expression of PPARγ2 is almost 
exclusively confined to the adipose tissue with only small amounts found in other tissues. 
In contrast, PPARγ1 is more or less ubiquitously expressed (505, 506). Another difference is 
that PPARγ2 exerts a several fold greater effect on insulin-stimulated transcriptional 
activity than PPARγ1 (507).  
d
b d
a b dPPARγ1
PPARγ2
PPARγ3
PPARγ4
mRNA Protein
c d
477 amino acids
477 amino acids
477 amino acids
505 amino acids
 
Figure 2.4 The different PPARγ mRNA isoforms (PPARγ1-4) are generated by alternative 
promote usage of the PPARγ gene (508). These give rise to two different protein isoforms; 
PPARγ1 with 477 amino acids and PPARγ2 with 505 amino acids shown on the right. A, b, and c 
represent different exon usage and d represents the six exons common for all PPARγ gene 
products. 
 
As all members of the PPAR family of nuclear transcription factors, PPARγ binds to the 
specific DNA response elements as a heterodimer with retinoid X receptor (RXR). Several 
ligands are able to bind PPARγ at the ligand binding domain and recruit co-activator 
complexes and promote the removal of co-repressor complexes (see section 2.6.3). Different 
PPARγ co-activators induce the expression of PPARγ target genes selectively, as 
underscored by PGC-1α, a major regulator of glucose metabolism, which for example 
activates UCP-1 in fat cells but not aP2, although both are PPARγ targets (509, 510). Both 
endogenous and synthetic ligands for PPARγ have been identified. Well known 
endogenous ligands include polyunsaturated fatty acids (393), prostaglandins (511), and 
oxidized lipids (512). Thiazolidinediones are synthetic PPARγ agonists that are used to 
treat T2DM attributable to their insulin-sensitizing effect (513).  
Actions of PPARγ in insulin sensitive tissues. PPARγ in adipose tissue. PPARγ 
activates transcription of genes involved in adipogenesis, e.g. aP2, PEPCK, CCAAT-
enhancer-binding protein (C/EBP)-α, perilipin, and GLUT4 (503, 504, 514-517). Ectopic 
PPARγ expression in fibroblasts (505) and myoblasts (518) sets off adipogenesis in these 
cells. Furthermore, PPARγ knock-out mice die in the embryonic state without having 
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generated any adipose tissue (519), and adipocytes in PPARγ +/+ , -/- chimeric mice 
predominantly derive from the PPARγ +/+ cells in contrast to other organs (520). In 
addition, several PPARγ missense mutations in humans cause partial lipodystrophy (521-
525). Although PPARγ has a pivotal role in adipogenesis, several multifactorial and 
interacting processes are also involved. Most notably, C/EBPβ and -δ transcription factors 
are activated by insulin and other adipogenic factors (526, 527) inducing PPARγ 
transcription that activates C/EBPα expression. C/EBPα in turn has the ability to further 
activate PPARγ transcription generating a positive feedback loop (526).  
Activation of PPARγ with thiazolidinediones promotes adipogenesis predominantly in 
subcutaneous adipose tissue (528). As a result, adipocytes take up circulating FFA and 
glucose and suppress their release thus promoting insulin sensitivity in all target organs for 
insulin. Thiazolidinediones are thought to mediate their insulin-sensitizing effect mainly by 
promoting subcutaneous adipose tissue proliferation and reversing lipid flux from harmful 
lipid depots, e.g. skeletal muscle, visceral fat, and subcutaneous fat, thereby alleviating 
lipotoxicity (529-532). In addition to expanding subcutaneous adipose tissue, adipocytes 
undergo morphological changes as PPARγ activation causes apoptosis of hypertrophied 
mature adipocytes and increases the number of small, newly formed and more insulin 
sensitive adipocytes (533-536). PPARγ agonists also induce the expression of UCP-1 in 
white adipose tissue (537), which is likely to result in increased adipocyte mitochondrial 
mass (538). These changes could enhance lipid oxidation and decrease triglyceride 
accumulation similar to brown fat (539) representing yet another mechanism of insulin 
sensitization. Studies in mice indicate that white adipose tissue (540) and expression of 
PPARγ in it (541) are critical for thiazolidinedione action.  
Interestingly, also a reduction of PPARγ activity can promote insulin sensitivity. 
Heterozygous PPARγ +/- deficient mice are protected from high fat diet-induced obesity 
and insulin resistance (542, 543). This is proposed to be due to increased FFA oxidation in 
the liver and skeletal muscle as FFA cannot be efficiently stored in subcutaneous adipose 
tissue in the partial absence of the PPARγ effect (544). This is in line with the observation in 
humans linking a single nucleotide polymorphism in the PPARG, which causes a reduction 
in PPARγ transcription activity, with insulin sensitivity (545, 546).  
The secretion of several metabolically active adipokines from the adipose tissue is 
directly or indirectly regulated by PPARγ. These include TNFα, adiponectin, visfatin, 
leptin, and resistin (535, 547-549). All these adipokines have been associated with insulin 
sensitivity (see section 2.3.3), suggesting possible links with PPARγ-induced insulin 
sensitization (498). 
PPARγ in skeletal muscle. PPARγ is expressed in skeletal muscle only to a small degree. 
Skeletal muscle is a major determinant of whole body insulin sensitivity and therefore even 
small changes in PPARγ action could have a significant effect at body level. Ablation of 
PPARγ in skeletal muscle in mice deteriorated insulin sensitivity which was not corrected 
by thiazolidinedione treatment suggesting that muscle PPARγ is a direct target of 
thiazolidinedione action (550). However, another study with muscle PPARγ knock-out 
mice reported normal glucose homeostasis but decreased hepatic insulin sensitivity due to 
increased white adipose tissue mass (551). As the actions of thiazolidinediones prevailed in 
spite of the absence of skeletal muscle PPARγ, it was concluded that the effects of 
thiazolidinediones are not dependent of skeletal muscle PPARγ. However, most studies 
indicate that skeletal muscle PPARγ coordinates energy usage but not directly insulin 
mediated glucose uptake in muscle (541, 552-555). In vitro PPARγ agonists enhance PI3K 
and Akt activation and GLUT4 translocation in muscle cells (556, 557). Thus, the role of 
skeletal muscle PPARγ in humans still remains controversial (498, 510).  
PPARγ in the liver. PPARγ is expressed in the liver at low levels. In rodent models 
PPARγ expression is induced in hepatic steatosis (540, 558). While normal liver packs lipids 
in VLDL particles for peripheral export, fat cells expressing PPARγ2 manifest with 
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increased hepatic de novo lipid synthesis and storage contributing to hepatic steatosis in 
vitro, an effect that is further augmented by thiazolidinedione application (326). Also 
activation of hepatic PPARγ in rodents promotes lipid accumulation and liver steatosis, 
and thiazolidinedione treatment in diabetic mice induces hepatic steatosis and this effect is 
abolished in liver-specific PPARγ knock-out mice (553). Conversely, in human studies this 
effect has not been seen and thiazolidinediones have been shown to be beneficial in non-
alcoholic fatty liver disease (325, 559, 560). Similar to adipose tissue and skeletal muscle, 
thiazolidinediones increase insulin sensitivity also in the liver (560, 561). The mechanism 
could be reduced delivery of FFAs into the liver and regulation of adipokine action (266, 
562). Importantly, in the absence of white adipose tissue, liver becomes the major site of 
thiazolidinedione action, highlighting the role of hepatic PPARγ in the regulation of whole 
body glucose and lipid metabolism (553). 
Human PPARγ gene variants and insulin sensitivity. Several human PPARγ genetic 
variants have been discovered that are associated with insulin sensitivity (reviewed in 
(563)). These mutations give information on the potential phenotypic mechanisms of 
PPARγ in the regulation of lipid and glucose metabolism. 
Loss-of-function mutations. A single nucleotide C→T change in the PPARG, causing a 
proline to leucine substitution at codon 467 (Pro467Leu) at the carboxy terminus of the LBD 
leads to severely impaired ligand binding and reduced target gene transcriptional activity 
(521). Consequently, heterozygous carriers of this mutation are prone to insulin resistance 
and T2DM, and display signs of partial lipodystrophy predominantly in the gluteal and 
limb depots instead of obesity (524). Due to lipodystrophy, these subjects are also prone to 
hepatic steatosis (hepatic lipotoxicity). Treatment with a PPARγ agonist drastically 
improves insulin sensitivity and alleviates the lipodystrophy (524). 
Another SNP (G→A) in PPARG results in a valine to methionine substitution 
(Val290Met). A subject carrying this mutation was severely insulin resistant with signs of 
similar partial lipodystrophy as in subjects heterozygous for the P467L mutation. However, 
thiazolidinedione treatment in a carrier of the Val290Met mutation was less effective than 
in a subject with the P467L mutation (524). 
Agarwal and Garg reported a C→T heterozygous substitution in exon 6 of the PPARG 
causing an arginine to cysteine substitution (Arg425Cys) (523). A female subject with this 
mutation also showed signs of partial lipodystrophy and developed T2DM. 
A frameshift mutation leading to a premature stop codon (185Stop) of PPARG and 
consequent formation of a mutant receptor incapable of transactivation of PPAR target 
genes in co-occurrence with another frameshift mutation (protein-phosphatase 1, 
regulatory subunit 3; PPP1R3A, involved in muscle glycogen synthesis) was identified in 
severely insulin resistant subjects demonstrating a strong mutation to mutation interaction 
(564).  
Cys114Arg, Cys131Tyr, and Cys162Trp polymorphisms of PPARG also cause a defect in 
PPARγ ability to bind to target PPRE and result in insulin resistance and lipodystrophy 
(565). Similarly, two mutations (Arg357X, 315Stop) causing missense or truncated proteins, 
respectively, can cause lipodystrophy (565). 
Gain-of function mutation. A rare gain-of-function mutation of PPARG (Pro115Gln) is 
characterized by failure of PPARγ2 serine phosphorylation that leads to constitutively 
active form of PPARγ2 (566). Consequently, subjects with this mutation are severely 
overweight, but have no signs of obvious insulin resistance. This resembles increased 
insulin sensitivity despite the weight gain observed in subjects using PPARγ agonists (567). 
The Pro12Ala polymorphism. The most common polymorphism of PPARG is a SNP 
C→T missense mutation leading to a substitution of proline to alanine at position 12 of 
PPARγ2 specific exon B (Pro12Ala polymorphism) which causes a 2-fold decrease in the 
transcriptional activation of the PPARγ target genes (545, 568). The frequency of the Ala12 
allele is variable in different ethnic populations ranging from 4% in Asian populations (569) 
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to 28% in Caucasian population (570) and around 20% in Finns (571, 572). However the 
frequency of the Ala allele is significantly lower in subjects with T2DM (545, 571) 
suggesting that this polymorphism associates with the risk of T2DM. 
Meta-analyses of several association studies have provided proof of a modest increase in 
T2DM risk in subjects carrying the Pro12Pro genotype (546, 573). Several genome-wide 
association studies have also replicated the association of the Pro12Ala polymorphism with 
T2DM (99-101). While the individual risk reduction by the Ala allele is only about 15%, this 
translates into a population attributable risk of 25% in Caucasians, since the Pro12Pro 
genotype is so common.  
The initial finding associated the Ala allele with improved insulin sensitivity and lower 
body mass index (545). However, several subsequent studies gave conflicting results, 
reporting associations with improved (574-578), impaired (579), or unaffected (580, 581) 
insulin sensitivity as well as lower (545, 582), higher (583-587), divergent effect on (588) or 
no effect on (589-591) body mass index. These apparent discrepancies are partly explained 
by different study settings, methods of determining insulin sensitivity in particular, and 
low number of participants, but can also be caused by gene-environment and gene-gene 
interactions. Altogether, most studies have showed improved insulin sensitivity to be 
associated with the Ala12 allele (508) and the Pro12Ala polymorphism is considered to be 
one of the best replicated genetic risk factors for T2DM (592). Recent findings show that the 
Pro12Ala polymorphism regulates insulin sensitivity already in children and adolescents 
(593). 
Accumulating evidence suggests that the effect of the Pro12Ala polymorphism on 
insulin sensitivity and T2DM risk is highly modulated by interaction with lifestyle and 
environmental factors. Because diet and physical activity are the major risk factors 
associated with T2DM, it is important to consider their interaction with the genes. Carriers 
of the Ala12 allele who consume high fat diet are protected from obesity (594) and they also 
benefit more from diet and exercise intervention than carriers of the Pro12Pro genotype 
(595-598), while the harmful effect of the Pro12Pro genotype seems to be more prominent in 
sedentary subjects (599). This polymorphism seems to regulate weight in response to 
environmental factors throughout the lifetime (595, 600-603). 
Since fatty acids are natural ligands for PPARγ, it is reasonable to propose that 
differences in dietary fat can modify the effect of this polymorphism on markers of insulin 
sensitivity and T2DM as suggested by several studies (594, 596, 603-605). However, the 
issue is further complicated by obesity status, with some studies suggesting an insulin-
sensitizing effect of the Ala12 allele to be present in lean subjects (545, 606, 607) and others 
in obese subjects (577, 608, 609). Also, ethnicity is likely to be an important factor behind the 
diverse effects of the Pro12Ala polymorphism. (590, 607, 610, 611). 
Gene-gene interactions modifying the effect of the Pro12Ala polymorphism have been 
reported. The Pro12Ala polymorphism has been shown to interact with a polymorphism of 
the hepatic nuclear factor-4α on insulin sensitivity (612), a Trp64Arg polymorphism of the 
β3-adrenergic receptor gene on obesity (613), a Gly972Arg polymorphism of the insulin 
receptor substrate gene (614), a K121Q polymorphism of the plasma cell glycoprotein-1 
(PC-1) gene (615), and a polymorphism (A-376C) in the  aP2 gene (616) on insulin 
sensitivity. Also, a T94G SNP of adiponectin gene has been reported to interact with the 
Pro12Ala polymorphism on insulin sensitivity (617). There is also evidence suggesting an 
opposing interaction of the Pro12Ala polymorphism with a C681G polymorphism of the 
PPARG promoter (618), and with a silent C1431T polymorphism of PPARG (619, 620). 
Effects of the Pro12Ala polymorphism. The mechanisms behind the effects of the Pro12Ala 
polymorphism on insulin sensitivity are currently unclear. Also, very little is known about 
how this polymorphism alters tissue-specific insulin action. However, since PPARγ2 is 
almost exclusively expressed in adipocytes, the mechanisms are primarily thought to arise 
from adipose tissue. Possible mechanisms could include direct effects of PPARγ on 
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transcriptional regulation of insulin signaling proteins, or reducing obesity associated 
inflammation in adipose tissue, indirect effects due to altered lipid handling, and possibly 
changes in adipokine secretion (621). The impact of obesity-associated induction of PPARγ2 
in other target tissues of insulin (622, 623) could further expand the role of PPARγ2 in 
regulation of insulin sensitivity. 
The Pro12Ala polymorphism and fatty acids. Since fatty acids impair insulin sensitivity 
causing lipotoxicity and they are proposed to be natural ligands for the key adipogenic 
receptor PPARγ, studies have focused on examining the effects of the polymorphism on 
fatty acid fluxes. FFAs arise from lipolysis mostly in adipose tissue. Under 
hyperinsulinemic euglycemic clamp conditions, lean subjects with the Ala12 allele have 
shown greater insulin-stimulated suppression of lipolysis, suggesting that reduced 
availability of FFA postprandially could explain at least partly the insulin-sensitizing effect 
of the Ala12 allele (574, 624, 625). However, in the fasting state circulating plasma FFA do 
not differ between carriers of the Ala12 allele and subjects with the Pro12Pro genotype 
independent of obesity (626). In addition, experimental elevation of FFA by lipid infusion 
during hyperglycemic clamp caused no difference in insulin sensitivity between the carriers 
of the Ala12 allele and the Pro12Pro genotype, but resulted in altered insulin secretion 
(627). It should also be noted that FFAs originating from visceral adipose tissue have direct 
access to the liver via portal circulation, and thus FFAs measured from plasma can be 
misleading at least with respect to visceral obesity and hepatic insulin sensitivity (628).  
The Pro12Ala polymorphism and adipokines. Some studies have suggested that release levels 
of adiponectin may differ between the subjects with the Pro12Pro genotype and the carriers 
of the Ala12 allele (572, 629), while others have found no such association (630, 631) or even 
an inverse correlation (632). Adiponectin is a key factor in the regulation of hepatic insulin 
sensitivity as it increases insulin’s suppressive action on hepatic glucose production (220). 
Interestingly, in Pima Indians hepatic glucose production was reduced more efficiently 
under insulin stimulation in subjects with the Ala12 allele compared to subjects 
heterozygous for the Pro allele (633).  
Other suggested mechanisms for action of the Pro12Ala polymorphism. Improved fuel selection 
as a marker of better metabolic flexibility has also been suggested to convey the insulin-
sensitizing effects of the Pro12Ala polymorphism. During insulin stimulation, male subjects 
with the Ala allele were able to suppress lipid oxidation more efficiently than subjects with 
the Pro12Pro genotype (631).  
Increased insulin clearance during the euglycemic and hyperglycemic clamp as well as 
during an OGTT has been found in subjects with the Ala12 allele compared to carriers of 
the Pro12Pro genotype even in the absence of a difference in whole body insulin sensitivity 
(625). This may reflect differences in hepatic insulin action or degradation as suggested by 
an animal model with defective hepatic internalization of IR bound insulin with a 
consequent hyperinsulinemia and insulin resistance (634). As insulin clearance is impaired 
in obesity and in other conditions with elevated FFAs (635), and hepatic glucose output is 
more efficiently suppressed in the Ala12 allele carriers under insulin stimulation (633), 
alterations in hepatic insulin sensitivity may explain some of the differences in insulin 
sensitivity at the whole body level between the different genotypes.  
Very recently a knock-in mouse model carrying the human Pro12Ala polymorphism was 
introduced (636). The most apparent difference in PPARγ2 expression was noticed in the 
liver between mice with the Pro12Pro and Ala12Ala genotypes, with the latter showing 
significantly lower expression levels. Interestingly, only a minor difference at the mRNA 
and protein expression levels was observed in adipose tissue between mice with different 
genotypes. On the chow diet, the Ala12Ala mice gained less weight despite equal food 
consumption, and this coincided with reduced fat mass and lean body mass. Also, in 
adipose tissue mice with the Ala12Ala genotype expressed less adipogenic proteins like 
aP2. The Ala12Ala mice were also more insulin sensitive, although no differences in fasting 
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FFAs, glucose, insulin, leptin, or adiponectin levels were noted between the Ala12Ala and 
Pro12Pro littermates. Most importantly, on high fat diet, the Ala12Ala mice tended to be 
more obese, and lost their insulin sensitivity. Adiponectin signaling was also different 
between the mice with different genotypes. These experiments highlight the key role of the 
Pro12Ala polymorphism in the adipose tissue to modulate the effect of PPARγ2 in the 
control of adipogenesis and interaction with environmental factors. Mice carrying the 
Ala12Ala genotype also had 13% longer lifespan, and a similar effect has also been 
proposed for humans (637).  
The C1431T polymorphism. A common silent polymorphism in exon 6 at nucleotide 
1431 of PPARG resulting in a C→T change (C1431T) has been positively associated with 
BMI (583, 638, 639) and risk of T2DM (620, 639). This polymorphism is in linkage 
disequilibrium with the Pro12Ala polymorphism and has been reported to interact with 
that polymorphism with regard to body weight (619) and risk of T2DM (620). In addition, 
the normoglycemic carriers of the T allele have been shown to be less prone to develop 
fasting hyperglycemia during a six-year follow-up in contrast to the subjects with the 
C1431C genotype (640). Also the role of this polymorphism in determining weight may be 
further modulated by gender (641). In conclusion, the C1431T polymorphism may influence 
the risk of T2DM and obesity, and this polymorphism could interact with the nearby 
Pro12Ala polymorphism. 
Promoter variants of PPARG. Four promoter variants (C-689T and C-2821T in promoter 
2, C-681G in promoter 3, and A-14G in promoter 4) have been described (633, 642-644). 
These variants have been associated with body weight, LDL cholesterol levels, 
lipodystrophy, metabolic syndrome and insulin sensitivity (563). 
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3 The aims of the study 
The aim of this study was to further characterize the impact of genetic variation in the 
PPAR genes on insulin sensitivity at the whole body level and in different insulin sensitive 
tissues.  The specific aims were as follows: 
 
1)  Does the Pro12Ala polymorphism of PPARG influence glucose uptake in skeletal 
muscle and adipose tissue? (Study I) 
 
2)  Does the Pro12Ala polymorphism of PPARG regulate hepatic glucose uptake? 
(Study II) 
 
3) Do polymorphisms in PPARD regulate glucose uptake in skeletal muscle and 
adipose tissue? (Study III) 
 
4)  Do polymorphisms in PPARA affect whole body insulin sensitivity or skeletal 
muscle and adipose tissue glucose uptake? (Study IV) 
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4 Subjects and methods 
4.1 STUDY POPULATIONS 
4.1.1 PET study population (I-IV) 
Non-diabetic subjects (I-IV). A total of 146 non-diabetic volunteers who had previously 
participated in PET studies at the Turku PET Center (Turku, Finland) were recruited for 
this study (645-649). Of these non-diabetic subjects a total of 124 subjects were available for 
Study I, 68 subjects for Study II, and 129 for Studies III and IV. Their adipose tissue, skeletal 
muscle and whole body glucose uptake rates were determined with combining 
hyperinsulinemic euglycemic clamp and [18F]FDG-PET scanning. The skeletal muscle blood 
flow was measured in 65 non-diabetic subjects using [15O]H2O and PET. For Study II we 
additionally assessed hepatic glucose uptake rates from 68 non-diabetic study subjects.  
Subjects with T2DM (II). For Study II we recruited an additional 105 subjects with 
T2DM, who had previously taken part in PET studies at the Turku PET Center (650, 651). 
Their whole body, adipose tissue, skeletal muscle, and hepatic glucose uptake rates were 
measured with hyperinsulinemic euglycemic clamp and [18F]FDG-PET scanning. T2DM 
was defined by the World Health Organization (WHO) criteria (49). Forty-six subjects with 
T2DM were receiving metformin, sulfonylurea, or both of these drugs.  None of the subjects 
with T2DM were using insulin, thiazolidinediones, or other antihyperglycemic 
medications.  
4.1.2 Non-diabetic offspring of subjects with T2DM (IV) 
Offspring of patients with T2DM (EUGENE2). For Study IV we recruited an independent 
study population of 217 offspring of patients with T2DM (probands) from the EUGENE2 
Study (652) at the University of Kuopio. The probands were randomly selected among 
patients with T2DM living in the Kuopio University Hospital region. A normal glucose 
tolerance, as assessed by an OGTT, was required for spouses of the probands. Offspring 
with known disease or medication affecting carbohydrate metabolism or pregnancy were 
excluded. Study subjects underwent hyperinsulinemic euglycemic clamp to measure their 
whole body glucose uptake rate, indirect calorimetry to assess their energy expenditure, 
glucose and lipid oxidation rates, OGTT and IVGTT to measure their glucose tolerance and 
insulin secretion. 
Participants from the METSIM Study. We also recruited another independent study 
population of 1794 men living in Kuopio, who had a non-diabetic OGTT according to the 
WHO criteria (49) and family history of diabetes, for Study IV to replicate the findings from 
EUGENE2 and PET-studies. These subjects were taking part in a population-based study 
(Metabolic Syndrome In Men, METSIM) aiming to investigate the effects of genetic factors 
on the risk of coronary heart disease and T2DM. Only those with a family history of 
diabetes were recruited to match this population with the population of offspring with 
T2DM. 
4.2 STUDY DESIGN AND METHODS 
4.2.1 PET Studies (I-IV) 
All PET studies were performed after an overnight fast at the Turku PET Center. Alcohol 
and caffeine consumption was prohibited 12 h before the study, and subjects were 
instructed to avoid strenuous physical activity one day before the study. In addition, those 
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subjects with T2DM using antidiabetic medication participating in Study II were informed 
not to take their antidiabetic medication in the study morning. Height, weight and blood 
pressure were measured using standard methods and BMI was calculated as: weight (kg) / 
height (m)2. Blood samples were drawn for fasting biochemical measurements before the 
clamp and PET studies were started. Blood samples were also collected for DNA analyses 
that were performed at the University of Kuopio. 
Hyperinsulinemic euglycemic clamp and [18F]FDG-PET scanning. During the clamp 
and PET scanning the subjects were lying down. One cannula was inserted in an 
antecubital vein for the infusion of glucose and insulin and the injection of [18F]FDG, and 
another in either the radial artery or the antecubital vein of the opposite upper extremity 
that was warmed with a heating pillow to arterialize venous blood. At 0 min a priming 
insulin dose was administered to reach the desired insulin level, where after a continuous 
intravenous insulin infusion of 1 mU·kg-1·min-1 was started for 140 ± 20 min. For 
determination of the input function, arterial or arterialized venous blood samples were 
drawn to measure the plasma radioactivity level. To measure the tissue-specific glucose 
uptake rates [18F]FDG was injected at 90 ± 30 min, and dynamic scans were performed to 
obtain images of the liver (18-50 min) and the femoral region (20-30 min). Due to the 
differences in primary study protocols, eighty-seven (42 without and 45 with T2DM) 
subjects performed intermittent isometric exercise with one leg during the scan. However, 
only the measurements of the non-contracting leg were used in our studies. The whole 
body insulin sensitivity was assessed using the hyperinsulinemic, euglycemic clamp 
technique (45). The levels of insulin and FFAs were determined every 30 or 60 min, 
respectively.  
Measurement of femoral muscle blood flow (I). In 65 subjects in Study I, the femoral 
muscle blood flow was determined using [15O]H2O and PET scanning. [15O]H2O was 
injected at 50±5 minutes intravenously and a dynamic scan for 6-15 minutes was carried 
out. The method to measure blood flow with [15O]H2O is based on the principle of inert gas 
exchange between blood and tissues (653). The arterial input curve was corrected for 
dispersion and delay and the autoradiographic method to calculate the blood flow pixel by 
pixel was applied, as previously described (83, 645).  
Production of PET tracers, image acquisition and processing. For Study I, 15O (t ½ = 123 
s) was generated in a low-energy deuteron accelerator (Cyclone 3, Ion Beam Application 
Inc., Louvain-la-Neuve, Belgium). [15O]H2O for measurement of femoral muscle blood flow 
was produced using a dialysis technique (654, 655). For Studies I-IV, [18F]FDG (t ½ = 109.8 
min) was synthesized using a cyclotron and computer-controlled apparatus according to 
the method described by Hamacher et al. (656). An eight-ring ECAT 931/08 (Siemens/CTI, 
Inc., Knoxville, TN) and GE Advance (General Electric Medical Systems, Milwaukee, WI) 
tomographs were employed. All data obtained were corrected for dead time, decay, scatter, 
random coincidences and measured photon attenuation and were reconstructed into a 128 × 
128 matrix. The Bayesian iterative reconstruction algorithm, using median root prior with 
iterations and a Bayesian coefficient of 0.3, was used for image processing (657). Photon 
attenuation was corrected by transmission scans on the femoral and abdominal region with 
a removable ring source containing 68Ge. Regions of interest (ROIs) were drawn in the 
anteromedial muscular compartment of the femoral region and the thickest area of 
subcutaneous fat usually located posterolaterally in four planes (Studies I-IV). 
Transmission images were utilized to ensure correct anatomical positioning of ROIs. Large 
blood vessels were avoided when outlining the regions. Free-shaped ROIs were drawn on 
multiple planes in the right lobe of the liver, avoiding large blood vessels (Study II). 
Calculations of the rates of skeletal muscle, subcutaneous adipose tissue (I-IV) and 
hepatic (II) glucose uptake. The three-compartment model of [18F]FDG kinetics was used to 
determine the rates of femoral muscle, subcutaneous adipose tissue and hepatic glucose 
uptake (87). Tissue and plasma time-activity curves were applied to generate a Patlak plot 
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for quantization of the fractional phosphorylation rate (Ki) for the [18F]FDG (89). The rates 
of glucose uptake were thereafter calculated by multiplying Ki gained from the graphical 
analysis by the prevailing plasma glucose concentration divided by LC, which accounts for 
the differences in transportation and phosphorylation of [18F]FDG and glucose. LC values 
of 1.2 for skeletal muscle, 1.14 for adipose tissue and 1.0 for liver were used (43, 44, 91). 
Calculations of the rates of whole body glucose uptake. Independently of the PET 
measurements, the rates of whole body glucose uptake were determined by the 
hyperinsulinemic euglycemic clamp (45). During insulin infusion euglycemia (plasma 
glucose, ~5 mmol/liter) was maintained by infusing 20% glucose at variable rates on the 
basis of blood glucose measurements taken at 10 min intervals. The whole body glucose 
uptake rates (M-values) were calculated from the glucose infusion rates between 60-120 
minutes i.e. after the steady state conditions were reached. The M-value (I-IV) and M-value 
divided by prevailing insulin concentration (M/I index) (IV) were used as estimates of the 
whole body insulin sensitivity. 
Biochemical analyses. Plasma glucose was determined by the glucose oxidase method 
(658). Serum insulin concentration was measured by immunoassay (659) and serum FFA 
concentration by a fluorometric method (660). Total cholesterol, high density lipoprotein 
cholesterol and serum triglycerides were assessed using standard enzymatic methods 
(Roche Molecular Biochemicals, Mannheim, Germany) with a fully automated analyzer 
(Hitachi 704, Hitachi, Tokyo, Japan). LDL cholesterol was calculated using the Friedewald 
equation (661).  
4.2.2 EUGENE2 and METSIM Studies (IV) 
EUGENE2 Study. Study design and anthropometric measurements. Participants came for 
the study after fasting for at least 12 hours. Their height and weight were measured using 
standard methods and BMI calculated as: weight (kg) / height (m)2. Blood pressure was 
determined applying regular mercury sphygmomanometer after a 5-min rest. Fasting blood 
samples were drawn and a 2-hour-OGTT was thereafter performed. On the second study 
day, after 12-hour fast, indirect calorimetry was performed for 30 minutes followed by an 
IVGTT and hyperinsulinemic euglycemic clamp, respectively. During the last 30 minutes of 
the 120-min clamp, indirect calorimetry was repeated. 
Oral and intravenous glucose tolerance tests. After glucose (75g) ingestion, blood 
glucose, FFA, and insulin measurements were performed at 30-min intervals up to 120 min 
(49).  
To determine insulin secretion, an intravenous glucose tolerance test was performed 
(662). A cannula was inserted in antecubital vein for the infusion of a 300 mg/kg bolus of 
50% glucose. Another cannula was inserted into the dorsal vein of the opposite hand for 
blood sampling. This hand was heated to arterialize the venous blood. After the glucose 
bolus, blood samples for glucose and insulin measurements were drawn at -5, 0, 2, 4, 6, 8, 
10, 20, 30, 40, 50 and 60 minutes.  
The trapezoidal method was used to calculate the incremental glucose and insulin areas 
under the curve (AUC). 
Indirect calorimetry. A computerized flow-through canopy gas-analyzer (DELTATRAC, 
TM Datex, Helsinki, Finland) was applied for indirect calorimetry. Subjects were at rest in 
the supine position during the 30 min gas exchange analysis both before clamp (fasting) 
and during the last 30 minutes of clamp. The data gained during the last 20 minutes of 
indirect calorimetry were used for the calculation of the rates of glucose and lipid 
oxidation. The fraction of non-oxidative glucose metabolism during the clamp was 
estimated by subtracting the rate of glucose oxidation from the total glucose infusion rate. 
Hyperinsulinemic clamp. After the fasting indirect calorimetry and an IVGTT were 
performed, a primed (10 min) insulin infusion followed by continuous infusion of insulin at 
40 mU/min/m2 body surface area was given to cause hyperinsulinemia. 20% glucose was 
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infused at varying rates to ensure normoglycemia (glucose clamped at target 5.0 mmol/l). 
Blood glucose was monitored every 5 min. The rate of the whole body glucose uptake (M-
value) was calculated from the glucose infusion rate during of the last 20 minutes of the 
clamp. 
Biochemical assays. Blood and plasma glucose was determined by the glucose oxidase 
method (Glucose & Lactate analyzer 2300 Stat Plus, Yellow Springs Instrument Co., Inc, 
Ohio, US). Insulin was determined by immunoassay (Phadeseph Insulin RIA 100, 
Pharmacia Diagnostics, Uppsala, Sweden). FFAs were determined by an enzymatic method 
(Wako Chemicals GmbH, Neuss, Germany). 
METSIM Study. Participants from the METSIM study underwent an OGTT (75g of 
glucose) after a 12-hour fast. Blood samples for glucose and insulin measurements were 
drawn at 0, 30 and 120 minutes. Plasma glucose was determined by the enzymatic 
hexokinase photometric assay (Konelab Systems Reagents, Thermo Fischer Scientific, 
Vantaa, Finland). Serum insulin was measured by immunoassay (ADVIA Centaur Insulin 
IRI, no 02230141, Siemens Medical Solutions Diagnostics, Tarrytown, NY, USA). The 
trapezoidal rule was utilized to calculate the insulin and glucose incremental AUCs. 
Insulinogenic index was calculated as the ratio of the increment of insulin to that of plasma 
glucose 30 minutes after the glucose ingestion (30 min insulin – fasting insulin)/(30 min 
glucose – fasting glucose) (663). Lean body mass was determined by bioelectrical 
impedance (RJL Systems, Detroit, MI, USA) in the supine position. Height and weight were 
measured by common methods and BMI was calculated as weight (kg) / height (m)2. 
4.2.3 Genotyping (I-IV) 
Genotyping for all studies was done at the University of Kuopio. Taqman allelic 
discrimination assays were employed (Applied Biosystems, Foster City, CA, USA). The 
genotyping reaction was amplified with a GeneAmp polymerase chain reaction (PCR) 
system 2700. Fluorescence was detected by ABI Prism 7000 sequence detector (Applied 
Biosystems, Foster City, CA, USA). Genotyping success was 100%. 
Selection of the SNPs for Study III. For Study III the selection of SNPs was based on 
genotype data available from the HapMap project website (664). Linkage disequilibrium 
statistics was calculated and haplotype blocks visualized using the Haploview software 
(665). A total of six SNPs were chosen for genotyping to ensure proper coverage of the 
whole genomic region of PPARD. 
Selection of the SNPs for Study IV. The selection of SNPs for Study IV was based on 
previous association studies (470,471), genotype data available from the HapMap project 
website (664), and the Tagger software (666). Altogether 11 SNPs were genotyped for 
PPARA and 10 of these covered > 90% of common variants with minor allele frequency >5% 
within PPARA. Linkage disequilibrium calculations and haplotyping were performed using 
the Haploview software (665). 
4.2.4 Statistical methods  
Studies I-III. The general linear model was used to estimate the statistical significance and 
the effect of covariates of established differences in variable means between the genotypes 
and haplogenotypes. This was done with the SPSS/Win statistical software (versions 10.0, 
11.5.1 and 13.0 for Windows, SPSS, Inc., Chicago, IL, USA). P-value < 0.05 was regarded as 
statistically significant. Data are given as mean ± standard deviation (SD). All variables 
with a skewed distribution were logarithmically transformed to achieve a normal 
distribution. Interaction between BMI and genotype on measures of insulin sensitivity was 
determined by linear regression. 
Study IV. Data analysis was performed with the SPSS/Win 13.0 software (SPSS, Inc., 
Chicago, IL,USA). Variables with a skewed distribution were logarithmically transformed. 
Data are expressed as mean ± SD. For participants of the EUGENE2 Study the adjustment 
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for confounding factors was done by applying the linear mixed model, with pedigree 
(family number) as a random factor, genotype and gender as fixed factors and other 
variables as covariates. For participants of the METSIM and PET studies the linear mixed 
model was applied. 
4.3 APPROVAL OF THE ETHICAL COMMITTEES (I-IV) 
After all subjects were informed about the purpose, nature and potential risks of the study, 
all subjects gave a written informed consent. The study protocol for subjects, who 
participated in PET studies, was approved by the Ethics Committee of the Hospital District 
of South-West Finland (Turku, Finland) and for subjects taking part in the EUGENE2 or 
METSIM studies by the Ethics Committee of the University of Kuopio. 
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5 Results 
5.1 THE PRO12ALA POLYMORPHISM OF PPARG (I-II) 
The effect of the Pro12Ala polymorphism on the rates of whole body, skeletal muscle, 
and subcutaneous adipose tissue glucose uptake in non-diabetic subjects (I). The 
frequency of the Ala12 allele was 0.17 and the observed genotype frequencies were 
consistent with the Hardy-Weinberg equilibrium. Because we found a significant statistical 
interaction between the effect of the Pro12Ala polymorphism and BMI on the rate of 
skeletal muscle glucose uptake (p=0.009), the subjects were divided into the obese (n=52) 
and non-obese (n=72) groups (BMI cutoff point 27 kg·m-2). There were no statistical 
differences in the allele frequencies of the Pro12Ala polymorphism between the obese and 
non-obese groups (0.16 vs. 0.17, P=0.947). Only 7 subjects carried the Ala12Ala genotype, 
and therefore the Pro12Ala and the Ala12Ala genotypes were combined for statistical 
analyses (Pro12Pro vs. X12Ala (either Pro12Ala or Ala12Ala)). The baseline characteristics 
of the study groups are shown in Table 5.1. 
 
Table 5.1 Baseline characteristics of the participants of Study I. 
 Non-obese Obese P 
N (men/women) 72 (67/5) 52 (42/10)  
Age (years) 29.6±8.5 35.4±11.4 0.001 
Weight (kg) 73.9±8.4 103.4±16.0 <0.001 
BMI (kg/m2) 23.0±2.0 32.3±3.9 <0.001 
Systolic blood pressure (mmHg) 124.8±15.1 134.4±12.4 <0.001 
Diastolic blood pressure (mmHg) 78.6±10.8 83.9±9.8 0.007 
Total cholesterol (mmol/l) 4.39±0.82 4.74±1.01 0.056 
LDL cholesterol (mmol/l) 2.66±0.77 2.94±0.94 0.093 
HDL cholesterol (mmol/l) 1.29±0.30 1.20±0.39 0.181 
Total triglycerides (mmol/l) 1.03±0.54 1.34±0.94 0.037 
Fasting glucose (mmol/l) 5.3±0.4 5.5±0.5 0.030 
Fasting insulin (pmol/l) 34.1±16.3 67.9±33.5 <0.001 
Fasting FFA (mmol/l) 0.53±0.19 0.63±0.22 0.014 
Data are represented as means ± SD. BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; 
FFA, free fatty acid concentration. Non-obese, BMI < 27 kg/m2; Obese, BMI ≥ 27 kg/m2. P-values are for the difference 
between groups (independent t-test). 
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Whole body, skeletal muscle, and subcutaneous adipose tissue glucose uptake. In non-obese 
subjects, the rate of skeletal muscle glucose uptake during hyperinsulinemia was higher in subjects 
carrying the Ala12 allele than in subjects carrying the Pro12Pro genotype (62.8 ± 26.3 vs. 46.4 ± 
20.8 μmmol∙kg-1∙min-1, P=0.004, respectively, adjusted for gender and age) (Figure 5.1B). Similarly, 
the rate of whole body glucose uptake was higher in subjects with the Ala12 allele than in subjects 
with the Pro12Pro genotype in non-obese group (40.9 ± 14.6 vs. 34.4 ± 12.5 μmmol∙kg-1∙min-1, 
respectively), but the difference was not statistically significant (P=0.055, adjusted for gender and 
age) (Figure 5.1A). However, additional adjustment for BMI increased the statistical significance of 
the observed difference (P=0.019). No difference in adipose tissue glucose uptake rate according to 
the Pro12Ala polymorphism was detected (Figure 5.1C). There was no difference in femoral muscle 
blood flow between genotypes in the non-obese group (3.0 ± 2.1 vs. 2.8 ± 1.7 ml∙kg-1∙min-1; Ala12 
allele vs. Pro12Pro genotype, respectively, P=0.786). 
In contrast to the results of the non-obese group, we found no significant differences in 
the obese group between subjects carrying the Ala12 allele and subjects with the Pro12Pro 
genotype in the rates of whole body (18.7 ± 9.6 vs. 18.2 ± 9.6 μmmol·kg-1·min-1, P=0.872), 
skeletal muscle (24.4 ± 13.3 vs. 30.3 ± 21.3 μmmol·kg-1·min-1, P=0.283) or adipose tissue (10.7 
± 6.1 vs. 10.3 ± 5.0 μmmol·kg-1·min-1, P=0.946) glucose uptake, respectively (Figure 5.1A-C). 
Similarly, no difference in the femoral blood flow between obese carriers of the Ala12 allele 
and the Pro12Pro genotypes was found (2.1 ± 0.8 vs. 3.2 ± 2.6 ml·kg-1·min-1, respectively, 
P=0.121). 
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Figure 5.1 The effect of the Pro12Ala polymorphism of PPARG on the rates of whole body (A), 
skeletal muscle (B), and subcutaneous adipose tissue (C) glucose uptake in non-obese and 
obese subjects. The white bars represent subjects with the Pro12Pro genotype, the hatched 
bars represent carriers of the Ala12 allele, and error bars indicate +SD. P-values (analysis of 
covariance) adjusted for gender and age. 
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The effect of the Pro12Ala polymorphism on hepatic glucose uptake in non-diabetic 
subjects and in subjects with T2DM (II). In Study II, we measured the rates of hepatic 
glucose uptake in the carriers of the different genotypes of the Pro12Ala polymorphism 
during the hyperinsulinemic euglycemic clamp. Data were available for 68 non-diabetic 
subjects, 51 of whom were among the participants of Study I, and 105 subjects with T2DM. 
Due to a small number of subjects with the Ala12Ala genotype, subjects with the Pro12Ala 
and Ala12Ala genotypes were combined in statistical analyses. Subjects were divided into 
obese (BMI>27 kg·m-2; non-diabetic subjects: n=30; 18 Pro/Pro, 12 X/Ala; Subjects with 
T2DM: n=78; 60 Pro/Pro, 18 X/Ala) and non-obese (BMI<27 kg·m-2; non-diabetic subjects: 
n=38; 27 Pro/Pro, 11 X/Ala; subjects with T2DM: n=27; 19 Pro/Pro, 8 X/Ala) groups using the 
same cutoff point of 27 kg·m-2 as in Study I, because in Study II a significant statistical 
interaction between the effect of the Pro12Ala polymorphism and BMI on hepatic glucose 
uptake rate (P=0.001) was observed. 
Non-diabetic subjects. No differences in BMI, fasting glucose, insulin, FFA levels and 
FFA levels during clamp according to the Pro12Ala polymorphism was found in the non-
obese group (data not shown), whereas obese carriers of the Ala12 allele had higher fasting 
plasma glucose than subjects with the Pro12Pro genotype (5.6 ± 0.4 vs. 5.3 ± 0.4 mmol·l-1, 
respectively). Obese subjects carrying the Ala12 allele had somewhat higher rate of hepatic 
glucose uptake compared with that in subjects with the Pro12Pro genotype (25.3 ± 11.5 vs. 
19.8 ± 6.6 μmmol·kg-1·min-1, respectively), but this difference did not reach statistical 
significance (P=0.137, Figure 5.2B). In non-obese subjects no difference in the rate of hepatic 
glucose uptake between the carriers of the Ala12 allele (19.4 ± 9.7 μmmol·kg-1·min-1) and 
subjects with the Pro12Pro genotype (20.8 ± 8.0 μmmol·kg-1·min-1) was observed (P=0.588, 
Figure 5.2B). 
Subjects with T2DM. The frequency of the Ala12 allele was 0.13 in subjects with T2DM 
and 0.19 in non-diabetic subjects (P=ns). Subjects with the Pro12Ala and Ala12Ala 
genotypes were combined in statistical analyses. We found no differences between subjects 
with the Pro12Pro genotype and subjects carrying the Ala12 allele in the rates of whole 
body, skeletal muscle, or adipose tissue glucose uptake either in the non-obese or obese 
group (Figure 5.3). However, obese subjects with T2DM carrying the Ala12 allele had 
higher rate of hepatic glucose uptake than obese subjects with the Pro12Pro genotype 
(21.0±10.6 vs. 15.1±5.1 μmol·kg-1, respectively (P=0.001, Figure 5.2A). In contrast, the rate of 
hepatic glucose uptake in non-obese subjects with T2DM did not differ according to their 
genotypes (21.8±7.8 μmol·kg-1·min-1 in carriers of the Ala12 allele and 22.2±10.6 μmol·kg-
1·min-1 in subjects with the Pro12Pro genotype, P=0.697).  
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Figure  5.2 The effect of the Pro12Ala polymorphism of PPARG on the rates of hepatic glucose 
uptake in non-obese and obese diabetic (A) and non-diabetic (B) subjects, Study II. White bars 
indicate the Pro12Pro genotype carriers; black bars indicate carriers of the Ala12 allele. Error 
bars indicate SD. (analysis of covariance, in diabetic subjects adjusted for gender, age, the use 
of oral antidiabetic drug treatment and exercise during the clamp, and in non-diabetic subjects 
adjusted for gender, age and exercise during the clamp). 
  
44 
 
 
 
   
Figure 5.3 The effect of the Pro12Ala polymorphism of PPARG on the rates of whole body (A), 
skeletal muscle (B), and subcutaneous adipose tissue (C) glucose uptake in non-obese and 
obese subjects with T2DM, Study II. White bars indicate the Pro12Pro genotype carriers; black 
bars indicate carriers of the Ala12 allele. Error bars indicate SD. (analysis of covariance, 
adjusted for gender, age, the use of oral antidiabetic drug treatment and exercise during the 
clamp).  
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5.2 SNPS OF PPARD AND INSULIN SENSITIVITY (III) 
5.2.1 Baseline characteristics 
We selected six SNPs of PPARD for genotyping; rs6902123, rs2267668, rs2016520, rs2076167, 
rs1053049, and rs3734254. Data for linkage disequilibrium and the location map of the 
selected SNPs are shown in Figure 5.4. All the observed allele frequencies were in Hardy-
Weinberg equilibrium. Minor allele frequencies were 0.03 for rs6902123, 0.13 for rs2267668, 
0.14 for rs2016520, 0.14 for rs2076167, 0.14 for rs1053049, and 0.12 for rs3734254. No subjects 
were found to be homozygous for the minor alleles of any of the genotyped SNPs. 
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 SNPs D' 
 rs6902123 rs2267668 rs2016520 rs2076167 rs3734254 rs1053049 
rs6902123 - 0.974 0.132 1.000 0.426 1.000 
rs2267668 0.004 - 1.000 0.758 0.832 0.777 
rs2016520 0.003 0.863 - 0.821 0.935 0.825 
rs2076167 0.19 0.552 0.605 - 0.979 1.000 
rs3734254 0.038 0.652 0.711 0.869 - 1.000 
r2 
rs1053049 0.187 0.571 0.622 0.981 0.890 - 
 
Figure 5.4 A: Gene map shows single nucleotide polymorphisms (SNPs) genotyped in PPARD 
(NM_006238).  Coding exons are marked by black boxes and 5' and 3' untranslated regions by 
white boxes. Genotyped SNPs are shown with NCBI's dbSNP accession numbers.  B: Linkage 
disequilibrium (D', r 2) are shown among SNPs in PPARD. 
 
Table 5.2 shows the clinical characteristics and rates of glucose uptake according to the 
PPARD genotypes. At baseline, subjects with the AG genotype of rs2267668 had lower 
blood pressure compared with subjects with the AA genotype (124±14 vs. 131±15 mmHg, 
respectively, P=0.044). None of the selected genotypes were associated with BMI, but 
subjects with the TT genotype of rs2076167 had somewhat higher total and LDL cholesterol 
than subjects with the TC genotype. Likewise, subjects with the TT genotype of rs1053049 
had higher total and LDL cholesterol levels than those carrying the C allele (data not 
shown). However, after adjusting the results for age and gender, none of the SNPs were 
associated with total, LDL or HDL cholesterol levels. 
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5.2.2 SNPs in PPARD and glucose uptake 
Subjects with the TC genotype of rs6902123 had significantly higher rates of whole body 
glucose uptake (WBGU) (41.6±16.7 vs.  27.6±14.3 μmol·kg-1·min-1, P=0.005 adjusted for 
gender and age) and skeletal muscle glucose uptake (SMGU) (66.5±30.5 vs. 39.6±23.3 
μmol·kg-1·min-1, P=0.001 adjusted for gender and age) than those with the TT genotype. 
Also, subjects carrying the TC genotype of the rs2076167 had higher WBGU (34.4±13.8 vs. 
26.6±14.7 μmol·kg-1·min-1, P=0.022 adjusted for gender and age) and SMGU (50.4±23.7 vs. 
38.4±24.2 μmol·kg-1·min-1, P=0.023 adjusted for gender and age) than those carrying the TT 
genotype. Furthermore, subjects with the TC genotype of rs1053049 had higher WBGU 
(33.7±14.1 vs. 26.8±14.7 μmol·kg-1·min-1, P=0.029 adjusted for gender and age) and SMGU 
(50.0±23.8 vs. 38.6±23.8 μmol·kg-1·min-1, P=0.028 adjusted for gender and age) than subjects 
with the TT genotype. None of the genotyped SNPs in PPARD was associated with adipose 
tissue glucose uptake (SFGU). 
We found seven different haplotypes based on the six selected SNPs. Four of these were 
very uncommon (n=1-4) and thus inappropriate for statistical analyses. Therefore we 
constructed four haplogenotypes (HGT) according to the three SNPs (rs6902123, rs2076167, 
and rs1053049) showing the strongest association with WBGU and SMGU. Figure 5.5 shows 
the rates of WBGU, SMGU and SFGU in subjects with the HGT1 (TTT/TTT, n=97), HGT3 
(TCC/TTT, n=23), and HGT4 (CCC/TTT, n=8). Only one subject was found to carry the 
HGT2 (TTC/TTT), and therefore could not be included in statistical analyses. The rates of 
WBGU and SMGU differed between the HGTs (P=0.012 for WBGU; P=0.004 for SMGU, 
adjusted for gender and age), and subjects with the HGT1 had significantly lower WBGU 
(P=0.031 adjusted for gender and age) and SMGU (P=0.027 adjusted for gender and age) 
than those with HGT3 and HGT4. The difference in SFGU was not statistically significant 
(P=0.860) between different HGTs. 
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Figure 5.5 The rates of whole body (A), skeletal muscle (B) and subcutaneous adipose tissue 
(C) glucose uptake (mol/kg/min) according to haplogenotypes of PPARD, Study III. P values 
indicate the differences among the three haplogenotypes. Error bars indicate SD. Analysis of 
covariance, adjusted for age and gender. 
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5.3. SNPS OF PPARA AND INSULIN SENSITIVITY (IV) 
All SNPs were in Hardy-Weinberg equilibrium. Subjects homozygous for the rare alleles 
were combined with heterozygotes (dominant model) in statistical analyses, because the 
total number of these subjects was too low to allow separate analyses.  
5.3.1 EUGENE2 Study 
The associations of SNPs in PPARA with insulin sensitivity and insulin secretion are shown 
in Table 5.3. In the OGTT subjects with the AA genotype of rs8138102 had higher 2-hour 
glucose (P=0.042) and 2-hour insulin (P=0.038) than those with the AG genotype. Subjects 
with the AA genotype of rs4253776 had significantly lower WBGU (P=0.022) and non-
oxidative glucose disposal (p=0.006) during clamp than those carrying the G allele. During 
the clamp subjects carrying the AA genotype of rs8138102 had lower WBGU (P=0.018) and 
non-oxidative glucose disposal (P=0.005). Also, subjects with the XC genotype of rs135539 
had higher 2-hour insulin in an OGTT compared with those carrying the AA genotype 
(P=0.014). During the clamp subjects with the XC genotype had somewhat lower WBGU 
than subjects with the AA genotype, but the difference was not statistically significant 
(P=0.080). However, those with the XC genotype had significantly higher lipid oxidation 
during the clamp than subjects carrying the AA genotype (P=0.014). In addition, we found 
the subjects with the XG genotype of rs4253623 had higher 2-hour insulin (P=0.043) than 
subjects homozygous for the A allele. We found no association between the first-phase 
insulin secretion as assessed by insulin AUC between 0 and 10 minutes of the IVGTT and 
SNPs of PPARA. 
5.3.2 PET Study 
The association between SNPs in PPARA and rates of skeletal muscle and adipose tissue 
glucose uptake are shown in Table 5.3. Subjects with the AG genotype of rs4253776 had 
higher skeletal muscle GU/I index than subjects with the AA genotype (P=0.032). However, 
after adjusting for gender and age, this finding was of borderline statistical significance 
(P=0.059). Subjects with the XG genotype of rs8138102 had higher skeletal muscle GU/I 
index than subjects with the AA genotype (P=0.050), but this finding lost its statistical 
significance after adjusting for gender and age (P=0.109). No association between the SNPs 
of PPARA and adipose tissue glucose uptake was found. 
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5.3.3 METSIM Study 
The SNP rs8138102, which showed the strongest association in the EUGENE2 and PET 
Studies, was genotyped in 1794 non-diabetic middle-aged men with a family history of 
diabetes participating in the METSIM Study. We found that subjects with the XG genotype 
had lower BMI (26.7±3.6 vs. 27.2±3.8 kg·m-2, P=0.020), lower insulin AUC during an OGTT 
(36037±22771 vs. 39349±26637 pmol·l-1·min-1, P=0.026, and lower insulin AUC/glucose AUC 
during an OGTT (40.4±23.8 vs. 43.8±27.9, P=0.032). However, these results lost their 
statistical significance after adjusting for BMI, Table 5.4.  
 
 
 
 
Table 5.4 Association of the AA vs. XG genotypes of rs8138102 in PPARA with clinical and 
metabolic variables in 1794 non-diabetic men having a family history of T2DM (METSIM Study). 
SNP rs8138102  
Genotype (n) AA (1340) XG (454) P 
Age (years) 58.6±5.6 58.3±5.7 0.277 
BMI (kg/m2) 27.2±3.8 26.7±3.6 0.020 
Fat mass (%) 24.2±6.6 23.5±6.1 0.063 
Oral glucose tolerance test    
Fasting insulin (pmol/l) 8.3±5.5 7.7±4.6 0.057 
30-min insulin (pmol/l) 65.8±46.7 59.7±39.9 0.011a 
120-min insulin (pmol/l) 55.3±51.2 51.1±44.2 0.397 
Insulin AUC (pmol l-1 min-1) 39349±26637 36037±22771 0.026b 
Insulin AUC/ Glucose AUC 43.8±27.9 40.4±23.8 0.032c 
Insulinogenic index (pmol/mmol) 21.8±21.1 24.0±67.9 0.090 
 
P-values (general linear model) after adjustment for BMI: aP=0.078; bP=0.166; cP=0.177; SNP, single nucleotide 
polymorphism
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6 Discussion 
6.1 SUBJECTS AND METHODS 
6.1.1 PET study population (I-IV) 
To our knowledge this study included the largest number of participants so far whose 
whole body and tissue-specific insulin sensitivity were measured by the hyperinsulinemic 
euglycemic clamp and [18F]FDG-PET. However, due to the laborious, time-consuming and 
expensive study protocol involved in PET studies, the total number of study subjects 
remained fairly low for a cross-sectional genetic association study, which reduces the 
statistical power for detecting true associations. Also, the PET study population data was 
gathered by several different investigators, which raises the possibility of interindividual 
variation in the measurements of different parameters. 
Some study participants were scanned while they were performing isometric exercise 
with one leg. Therefore, only the results of the non-contracting leg were used to determine 
the skeletal muscle and adipose tissue glucose uptake rates. Also, regression analysis was 
employed in statistical analyses to adjust the results for this possible confounder. The PET 
study (Study II) included 105 subjects with T2DM, 46 of whom were on antidiabetic 
medication (metformin, a sulfonylurea, or both). The possibility that medication could have 
an effect on our results cannot be excluded, although it was taken into account in all 
statistical analyses. 
The PET study included somewhat more men than women, because of the exclusion of 
pregnant and possibly pregnant subjects from the study. Therefore, all results were 
statistically adjusted for gender. Non-diabetic study participants were considerably 
younger than subjects with T2DM, and thus direct comparison between the non-diabetic 
and diabetic groups is not possible. Ethnic differences in the effects of genetic variation of 
the PPAR genes have been reported, and the extrapolation of the findings of this study to 
other populations has to be done with caution. 
6.1.2 EUGENE2 and METSIM (IV) 
To determine the effect of SNPs in PPARA on insulin sensitivity, two additional study 
groups were recruited. The first of these included 217 healthy offspring of subjects with 
T2DM (EUGENE2 Study). This population is very suitable for genetic studies, because the 
lifetime risk for developing T2DM is almost threefold higher in the first-degree relatives of 
subjects with T2DM than the background population. In addition, insulin resistance is an 
early finding in these subjects and shows familial clustering (7, 667). These subjects 
underwent thorough phenotyping including measurements of height, weight and blood 
pressure by standard methods, an OGTT, an IVGTT, indirect calorimetry, and 
hyperinsulinemic euglycemic clamp to estimate glucose tolerance, insulin secretion and 
insulin sensitivity and glucose and lipid oxidation during fasting and clamp conditions. All 
these methods have been well characterized and validated and widely used in metabolic 
studies (45, 662, 668). The major disadvantages of these methods include complex, time-
consuming, laborious and expensive study protocols. 
Secondly, a large sample of 1794 middle-aged men with a family history of diabetes from 
an ongoing population based study (METSIM Study) was enrolled to confirm the findings 
of Study IV. These subjects underwent an OGTT to determine their glucose tolerance and 
insulin secretion. Again, this population is suitable for genetic studies due to the higher risk 
of T2DM and associated states. Furthermore, METSIM included somewhat older subjects 
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than EUGENE2 and PET study allowing better generalization of the results to population at 
large. 
6.1.3. Measurements of insulin sensitivity (I-IV) 
To determine the whole body insulin sensitivity we used the validated hyperinsulinemic 
euglycemic clamp technique (45), and to determine the tissue level insulin sensitivity under 
hyperinsulinemia we simultaneously applied the well validated method of [18F]FDG-PET 
for determining the rates of skeletal muscle, adipose tissue and hepatic glucose uptake (42, 
44). However, these methods measure insulin sensitivity only at the level of insulin 
stimulated glucose uptake and thus do not reflect all aspects of insulin sensitivity. 
[18F]FDG-PET only allows measurement of glucose uptake and phosphorylation rate. 
Furthermore, we did not directly assess hepatic glucose production but presumed it to be 
suppressed during the insulin infusion. However, it is possible that in subjects with T2DM 
this suppression was not complete (669). Similarly, the rate of whole body glucose uptake 
could be underestimated since the endogenous glucose production was not measured. It is 
unlikely, however, that these possible confounding factors are related to the PPARG 
genotype.  
In the METSIM Study, an OGTT was performed to assess the insulin sensitivity. While 
an OGTT is fairly inexpensive and simple procedure even for such a large sample, it gives 
only a rough estimate of individual insulin sensitivity. Despite the limitations (section 
2.1.3), an OGTT is fairly well validated against the clamp, and has been widely used in 
large study populations to estimate insulin sensitivity (5).  
6.1.4 Genotyping (I-IV) 
DNA samples were available for all study subjects. Genotyping was done applying 
commonly used TaqMan real-time PCR method and a 100% genotyping success was 
reached. In Studies II and IV, we regenotyped 7.3% and 3.8% of original samples 
respectively, with an error rate of 0%. In Studies I and II we genotyped a well known 
candidate SNP, while in Studies III and IV we chose the SNPs for genotyping from different 
haplotype blocks to properly cover the genomic region of PPARD and PPARA. Data from 
the HapMap project (664) and knowledge from previous association studies was used in 
the selection of the SNPs for genotyping. Despite these efforts, it is possible that our results 
may reflect true association of nearby genetic variants instead of the genotyped SNPs. We 
also constructed different haplotypes based on the genotyped SNPs in PPARD and PPARA 
in Studies III and IV, respectively, to gain more detailed information on the associations. 
6.2 THE PRO12ALA POLYMORPHISM AND INSULIN SENSITIVITY (I-II) 
We found a significant interaction between the effects of the Pro12Ala polymorphism and 
BMI on skeletal muscle glucose uptake during hyperinsulinemia, suggesting that in non-
diabetic subjects the effect of the Pro12Ala polymorphism on insulin sensitivity depends on 
adiposity. Subjects with BMI < 27 kg·m-2 carrying the Ala12 allele had higher rates of whole 
body and skeletal muscle glucose uptake than those carrying the Pro12Pro genotype, while 
no difference between the genotypes was observed in obese (BMI ≥ 27 kg·m-2) subjects. 
Although PPARγ2 is almost exclusively expressed in adipose tissue, we found no 
difference in adipose tissue glucose uptake either in non-obese or obese subjects. We also 
found that obese, non-diabetic subjects carrying the Pro12Pro genotype had somewhat 
lower hepatic glucose uptake rates than those carrying the Ala12 allele, although this 
finding did not reach statistical significance, possibly due to too few obese subjects. On the 
other hand, in the non-obese group the rates of hepatic glucose uptake under 
hyperinsulinemia were similar between the genotypes.  
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These results have several implications. First, it can solve some of the discrepancies 
between the earlier studies since insulin sensitivity was not previously investigated 
separately in obese and non-obese subjects. Our finding is also in line with a recent meta-
analysis showing that the reduction in the risk of T2DM in subjects carrying the Ala12 allele 
is greater in subjects with lower BMI (607). Previous studies have demonstrated higher 
insulin sensitivity in non-obese Ala12 carriers (670), and our study is the first to clearly 
demonstrate the difference in whole body and skeletal muscle insulin sensitivity. 
Importantly, our results indicate that although PPARγ2 is expressed primarily in adipose 
tissue, the effect of the Ala12 allele on glucose disposal is mediated through effects in other 
insulin sensitive tissues, mainly skeletal muscle. 
The Ala12 allele modestly reduces the transcription of PPARγ2 target genes. Since 
PPARγ2 is a major activator of adipogenesis (671), it is possible that non-obese subjects 
carrying the Ala12 allele are less prone to adiposity and weight gain and consequent insulin 
resistance (545, 546, 595, 672). Consequently, they seem to be more metabolically flexible in 
terms of changing from lipid to glucose oxidation upon glucose and insulin stimulation 
(631). However, under prolonged positive energy balance and in the context of obesity the 
Ala12 allele seems to become harmful (595, 636) and can even promote obesity (588, 673). In 
fact, carriers of the Ala12 allele have been shown to be more centrally obese than subjects 
with the Pro12Pro genotype (597). Under a high fat diet, the expression of PPARγ2 is 
increased in adipose tissue in normal mice and in the liver of obese mice (622). Indeed, 
environmental stimuli including diet and exercise are key modulators of the effects of the 
Pro12Ala polymorphism (563, 595, 596, 603).  
Our finding of higher hepatic glucose uptake in obese subjects carrying the Ala12 allele 
could be a compensatory mechanism to reduced skeletal muscle glucose uptake. Increased 
hepatic glucose uptake may coexist with increased hepatic lipid synthesis in the context of 
skeletal muscle and adipose tissue insulin resistance (674). Accordingly, increased 
triglyceride levels have been reported in obese carriers of the Ala12 allele compared to 
those with the Pro12Pro genotype (675).  Moreover, the Pro12Ala polymorphism may also 
regulate adipocyte hypertrophy (542, 676) and fat distribution (529). Interestingly, 
Vanginpurapu et al. have reported an association of the Pro12 allele with hepatic insulin 
resistance in a large male population sample (677). This finding is also in accordance with 
our results. Increased hepatic glucose uptake in obese subjects with T2DM carrying the 
Ala12 allele may reflect a counteracting mechanism for skeletal muscle and adipose tissue 
insulin resistance to overcome hyperglycemia. This could result in the reduction of the 
deleterious effects of long-lasting hyperglycemia. In agreement with this notion are several 
studies showing that carriers of the Ala12 allele have a reduced risk of diabetic 
complications (678-682). 
The mechanisms behind the insulin-sensitizing effect of the Pro12Ala polymorphism 
have not been completely elucidated. Several studies have suggested an important role of 
FFAs originating from adipose tissue, since FFAs are known to impair insulin sensitivity in 
skeletal muscle and liver. Subjects carrying the Ala12 allele are more sensitive to insulin’s 
antilipolytic action in peripheral tissues (624, 683). This would lead to a decrease in the 
levels of circulating FFAs and a subsequent increase in peripheral glucose disposal and 
insulin sensitivity (508). We did not find any differences in circulating FFA levels. 
However, hepatic FFA delivery through the portal circulation, which may play an 
important role especially in visceral lipolysis (628), was not measured. Therefore, it is 
possible that differences in FFA flux could explain our finding of higher hepatic glucose 
uptake in obese carriers of the Ala12 allele. In support, a recent paper has reported that the 
Pro12 allele is associated with decreased insulin sensitivity in adipocytes (677), which could 
lead to increased flux of FFA into the liver resulting in hepatic insulin resistance.  
Subjects with the Ala12Ala genotype have been reported to have higher adiponectin 
levels in some (572), but not all studies (610, 629, 630, 684). Again, these conflicting findings 
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may be explained by differences in ethnicity, gender, environmental factors, and obesity. 
Adiponectin is a known insulin sensitizer (685). Interestingly, Pro12Ala knock-in mice show 
that altered adiponectin signaling contributes to the insulin-sensitizing effect of the Ala12 
allele in lean mice (636). Also, adiponectin regulates hepatic insulin sensitivity, and 
adiponectin levels are inversely correlated with body weight (686). Therefore, differences in 
circulating adiponectin levels could at least in part explain the differences in the rates of 
glucose uptake in our study.  
6.3 PPARD AND INSULIN SENSITIVITY (III) 
Our results show that genetic variation in PPARD may affect insulin sensitivity especially 
in skeletal muscle. These results are in accordance with a previous study reporting that 
SNPs of PPARD predict the conversion of IGT to diabetes (494). Others have also reported 
an association of SNPs in PPARD with insulin sensitivity (493, 687) and features of the 
metabolic syndrome (688). However, a large population based study showed no correlation 
between variants of the PPARD and estimates of insulin sensitivity evaluated by an OGTT 
(485). The reasons for this discrepancy remain unclear. Furthermore, none of the large 
genome-wide association studies have implicated PPARD (687) as a locus associated with 
T2DM or related traits (689-692). Therefore, although genetic variation in PPARD is likely to 
influence insulin sensitivity, it seems not to be a major risk gene for T2DM. 
Animal studies have suggested an important role for PPARδ in the control of insulin-
stimulated glucose disposal and hepatic glucose production (453). Studies with PPARδ 
agonists have further emphasized the role of PPARδ in glucose and lipid metabolism (453, 
459, 460, 462, 476, 482, 693). However, a recent study has shown that the effects of the 
PPARδ agonists vary depending on species (694). 
In skeletal muscle, PPARδ is the most abundant isoform of all PPARs (456). Its 
expression is especially high in the oxidative type 1 fibers compared to type 2 fibers (458). 
Over-expression of PPARδ in skeletal muscle results in fiber type switch favoring type 1 
fibers (458, 478). In accordance, SNPs of PPARD have been associated with mitochondrial 
function and aerobic physical fitness (495) and body composition and adiposity during 
lifestyle intervention (496), that all are determinants of insulin sensitivity. Our results are in 
line with these observations and support a role of PPARδ in the regulation of skeletal 
muscle glucose metabolism. Also in humans the PPARδ agonist GW501516 ameliorated 
metabolic abnormalities in obese males (482). Activation of lipid oxidation by PPARδ could 
translate to reduced lipotoxicity, and consequently improved insulin sensitivity and β-cell 
function (695-697). These data clearly demonstrate the significance of PPARδ in metabolic 
regulation. Interestingly, a recent study reported that a SNP of PPARD (rs2016520) was 
associated with BMI and leptin levels differently in men and women suggesting a strong 
gender interaction in the effect of this polymorphism (698). Similarly, gene-gene and gene-
environment interactions modulate the effect of PPARD variants (494, 495, 699) and explain 
the discrepancy among the studies. 
Another possible mechanism behind the effect of PPARδ on insulin sensitivity arises 
from inflammatory pathways. As depicted previously, inflammation, cytokines and 
adipokines regulate insulin sensitivity (see sections 2.3.3 and 2.5). Macrophages residing in 
adipose tissue are a major source of these inflammatory mediators (700) and obesity is 
associated with increased macrophage infiltration in adipose tissue (701). Although all 
PPARs are involved in the regulation of immune responses and cytokine production (702), 
the role of PPARδ seems to be especially important (700). In fact, the activation of PPARδ 
suppressed inflammation (463), and the deletion of PPARδ in myeloid cells including 
macrophages induced insulin resistance and activated inflammatory pathways in mice 
(703). This evidence strongly suggests that PPARδ is an important factor in the regulation 
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of insulin sensitivity. Our finding that genetic variation in PPARD influences skeletal 
muscle glucose uptake gives evidence that PPARδ plays an important role in the regulation 
of insulin sensitivity. 
6.4 PPARA AND INSULIN SENSITIVITY (IV) 
Our findings suggest that SNPs in PPARA may influence insulin sensitivity. The effect was 
shown in particular in subjects with a high susceptibility for T2DM, namely subjects with a 
family history of diabetes. Support for our findings comes from a wide variety of sources. 
Although genome-wide association scans have not implicated PPARA as a risk gene for 
T2DM or insulin resistance, previous reports have suggested that SNPs of PPARA influence 
the age of onset and progression to T2DM (445, 446). In addition, the L162V polymorphism 
of PPARA is associated with the components of the metabolic syndrome and interacts with 
dietary fat intake (429, 436, 704, 705). Furthermore, the V227A polymorphism of PPARA 
interacts with dietary polyunsaturated fatty acid intake (448). Indeed, some of the 
discrepancy between different studies may arise from gene-gene interactions with SNPs of 
PPARA and other genes (439, 445, 446, 490). Additionally, the effect of SNPs of PPARA may 
also be modified by environmental factors, including diet (436, 448). This is expected as 
PPARα is known to play a key role in fatty acid oxidation in mitochondria (421). We also 
observed that SNPs of PPARA were associated with lipid oxidation in the fasting state and 
during insulin and glucose infusion.  
PPARα also regulates the expression of lipogenic genes in the liver. Both fatty acid 
oxidation and lipogenesis are major determinants of hepatic lipid content (391, 706). 
Accordingly, PPARα null mice are unable to oxidize fatty acids effectively and are prone to 
hepatic steatosis upon fasting (707). Hepatic steatosis is a common finding in insulin 
resistant states (312), although the causality of the association between hepatic steatosis and 
insulin resistance remains unclear (315, 708).  
Both excess fat intake in rodents and lipotoxicity impair insulin sensitivity. Effective 
lipid oxidation is crucial to counteract the harmful consequences of fatty acid excess. The 
activation of PPARα seems to preserve β-cell secretory function by increasing fatty acid 
oxidation and storage (425, 427, 709, 710).  PPARα agonist treatment has been shown to 
prevent lipotoxicity and even reverse insulin resistance in animal models (711-713). In 
contrast, skeletal muscle overexpression of PPARα increases fatty acid oxidation and 
reduces glucose uptake (421). The largest clinical trial on fibrates, the FIELD Study, did not 
show any effect of fenofibrate on glucose levels in subjects with T2DM (419). Thus, the 
effects of PPARα agonists on glucose metabolism remain ambiguous (391). 
We were unable to confirm an association between in vivo first-phase insulin secretion 
and SNPs in PPARA in healthy subjects with a family history of diabetes at high risk for 
T2DM. This is probably due to the limited size of our study. Therefore larger studies are 
warranted to examine whether SNPs in PPARA have an effect on insulin secretion capacity 
especially in prediabetic conditions such as impaired glucose tolerance, since PPARα 
activation may prevent the progression of prediabetic states to T2DM (391).  
PPARα is also involved in inflammatory control. PPARα ligands include inflammatory 
mediators including prostaglandins and leukotrienes (387), and PPARα regulates the 
expression of TNFα, IL-6 (714, 715), and NF-κB (716). Furthermore, PPARα knockout mice 
have abnormal responses to inflammatory stimuli (717, 718) and PPARα ligands (fibrates) 
have been shown to act in anti-inflammatory fashion (719, 720). Thus PPARα could affect 
insulin sensitivity also through regulation of inflammation, and therefore the measurement 
of inflammatory markers is needed in future studies evaluating the effects of genetic 
variation in PPARA on insulin secretion.  
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6.5 CONCLUDING REMARKS 
This study was targeted to examine the role of SNPs in the PPAR genes on insulin 
sensitivity. Clearly, all PPAR isoforms are important regulators of glucose and lipid 
metabolism, energy balance and thus are key players in determining insulin sensitivity 
both in an organ-specific manner and at the whole body level. Our results suggest that 
genetic variation in PPAR genes may explain individual differences in insulin action, and 
therefore could also influence the risk for T2DM and associated prediabetic states. Genetic 
variation in PPAR genes may also alter the effect of antidiabetic and cardiovascular 
medication. This is particularly relevant because all PPAR isoforms are currently targets in 
the development of new drugs for diabetes and cardiovascular disease (721, 722). The 
complexity of our study protocol allowed only a limited number of study subjects. 
Therefore larger studies are needed to further characterize how genetic variants in the 
PPAR genes affect insulin sensitivity both at the organ-specific and whole body level. 
Future studies should be aimed at more thorough characterization of insulin sensitivity 
in different tissues and the complex interplay of these tissues in determining whole body 
insulin sensitivity. Also, the role of PPARs in the regulation of glucose and lipid 
metabolism needs further clarification. What are the main regulatory pathways behind the 
action of PPARα, -δ, and –γ, and how does signaling through these routes differ between 
individuals with different genotypic variants? What are the roles of obesity, environmental 
factors and genetic interactions in modulating the effects of PPAR gene variants? Moreover, 
how do these differences in the regulation of energy metabolism translate into individual 
differences in the risk of insulin resistance and T2DM? Also, other mechanisms like 
posttranslational processing of proteins and epigenetic regulation could modify the effects 
of PPAR genes, and further studies in these fields are called for.  
Although recent GWAS have confirmed only the association of one SNP of PPAR genes 
(the Pro12Ala polymorphism) with T2DM, it is unclear why these studies have identified 
only a few variants regulating insulin sensitivity to be associated with T2DM with most 
variants identified regulating insulin secretion. Therefore we also need further studies 
investigating the relationship of insulin sensitivity and insulin secretion in the pathogenesis 
of T2DM. 
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7 Summary 
AIM I 
Higher rates of skeletal muscle and whole body glucose uptake in non-obese non-diabetic 
subjects carrying the Ala12 allele than in subjects with the Pro12Pro genotype of PPARG 
were found. In overweight and obese subjects no differences in the rates of whole body, 
skeletal muscle, or subcutaneous adipose tissue glucose uptake were found. These results 
indicate that the Pro12Ala polymorphism of the PPARG regulates insulin sensitivity in 
these tissues and at the whole body level depending on the degree of adiposity. 
AIM II 
A significantly higher hepatic glucose uptake in obese subjects with T2DM carrying the 
Ala12 allele than in subjects with the Pro12Pro genotype of the PPARG gene was observed. 
A similar difference in hepatic glucose uptake was found between obese non-diabetic 
carriers of the Ala12 allele and subjects with the Pro12Pro genotype, but this difference did 
not reach statistical significance. These results imply that the Pro12Ala polymorphism of 
the PPARG influences hepatic glucose uptake depending on obesity. 
 
AIM III 
Three SNPs of PPARD (rs6902123, rs2076167, rs1053049) and their haplogenotypes were 
associated with whole body insulin sensitivity and skeletal muscle glucose uptake during 
insulin infusion in 129 non-diabetic subjects, suggesting that genetic variation in PPARD 
clearly regulates skeletal muscle glucose uptake.  
 
AIM IV 
Two (rs4253776 and rs8138102) of eleven SNPs of PPARA were associated with whole body 
insulin sensitivity in non-diabetic offspring of subjects with T2DM. These SNPs were also 
associated with skeletal muscle glucose uptake in non-diabetic subjects, and rs8138102 was 
also associated with insulin AUC in an OGTT in an independent sample of non-diabetic 
men with a family history of diabetes. These findings imply that genetic variation in the 
PPARA may affect insulin sensitivity at the whole body and skeletal muscle level. 
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All three members of the peroxisome 
proliferator-activated receptors 
(PPAR-α, -δ and -γ) are key regulators 
of human energy metabolism 
and candidate genes for insulin 
resistance. In this thesis, the effect 
of single nucleotide polymorphisms 
(SNPs) in the PPAR genes on insulin 
sensitivity was investigated at the 
whole body and tissue-specific level. 
The results demonstrate that SNPs 
in all PPAR genes may affect insulin 
sensitivity, suggesting that variation 
in the PPAR genes could also 
influence the risk of type 2 diabetes 
mellitus.
